A Phase 3 interventional study of Aflibercept and Faricimab in Diabetic Macular Edema, sponsored by Hoffmann-La Roche. Completed at 185 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-11.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing faricimab in Macular Edema — 1 open to participants now, 3 under way, none of them phase 3. faricimab · Macular Edema.
Among the 13 studies testing faricimab in Macular Edema, this one is the 3rd largest by enrollment, is one of 2 that started in 2018, is one of 7 in phase 3, and was the 3rd registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →1 of the 13 studies testing faricimab in Macular Edema is open now. Recruiting first, the newest first:
Birmingham and Midland Eye Centre Sandwell and west Birmingham NHS trust
Ages 18+
faricimab: first FDA approval 2022 (VABYSMO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2018.
This study's enrollment of 940 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 229 across the 13 interventional studies. Of the 8 that completed or were terminated, 8 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 13 have an industry lead sponsor. The 6 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
28 studies in Macular Edema by Hoffmann-La Roche: 1 open now, 5 under way, 1 of them phase 3. Of 23 finished, 17 (74%) have results posted.
Among the 28 studies in Macular Edema by Hoffmann-La Roche, this one is the 3rd largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2018, is one of 14 in phase 3, and was the 10th registered.
Hoffmann-La Roche’s Macular Edema studies by the year they started, since 2007.
2 of the studies testing faricimab in Macular Edema that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05610319McMaster UniversityTreat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial | 2026-12 |
| NCT05224102Genentech, Inc.A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema | 2027-01-26 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies testing faricimab in Macular Edema, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 28 in Macular Edema:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.
Drug: Faricimab · Procedure: Sham Procedure
Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections once every 4 weeks (Q4W), 8 weeks (Q8W), 12 weeks (Q12W), or 16 weeks (Q16W) up to Week 96, followed by the final study visit at Week 100.
Drug: Faricimab · Procedure: Sham Procedure
Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Drug: Aflibercept · Procedure: Sham Procedure
Aflibercept 2 mg was administered by intravitreal (IVT) injection into the study eye once every 8 weeks (Q8W).
Also known as: Eylea
Faricimab 6 mg was administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or according to a personalized treatment interval (PTI) in arm B.
Also known as: VABYSMO™, RO6867461, RG7716
The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in all three treatments arms at applicable clinic visits to maintain masking among treatment arms.
Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded. 97.5% CI is a rounding of 97.52% CI.
Time frame: From Baseline through Week 56
Percentage of Participants With a ≥2-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale at Week 52, ITT and Treatment-Naive Populations
The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 97.5% confidence interval (CI) is a rounding of 97.52% CI.
Time frame: Baseline and Week 52
Change From Baseline in BCVA in the Study Eye Over Time, ITT Population
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded. 95% CI is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population
Best-Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline BCVA (continuous), baseline BCVA (\<64 vs. ≥64 letters), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT Population
BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, average of Weeks 48, 52, and 56
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Percentage of Participants Gaining ≥15, ≥10, ≥5, or ≥0 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, Treatment-Naive Population
BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, average of Weeks 48, 52, and 56
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Percentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT Population
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, average of Weeks 48, 52, and 56
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Percentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, Treatment-Naive Population
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, average of Weeks 48, 52, and 56
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations
BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, average of Weeks 48, 52, and 56
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations
BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥69 vs. \<69 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, average of Weeks 48, 52, and 56
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥69 vs. \<69 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥69 vs. \<69 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations
BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, average of Weeks 48, 52, and 56
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement invisual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Percentage of Participants With a ≥2-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population
The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 16, 52, and 96
Percentage of Participants With a ≥2-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population
The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 16, 52, and 96
Percentage of Participants With a ≥3-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population
The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 16, 52, and 96
Percentage of Participants With a ≥3-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population
The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 16, 52, and 96
Percentage of Participants With a ≥4-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population
The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 16, 52, and 96
Percentage of Participants With a ≥4-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population
The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 16, 52, and 96
Percentage of Participants Without Proliferative Diabetic Retinopathy (PDR) at Baseline Who Developed New PDR at Week 52, ITT and Treatment-Naive Populations
The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy (PDR). PDR was defined as an ETDRS DRSS score of ≥61 on the 7-field/4-wide field color fundus photographs assessment by a central reading center. The weighted percentages of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% CI is a rounding of 95.04% CI.
Time frame: Baseline and Week 52
Percentage of Participants Without High-Risk Proliferative Diabetic Retinopathy (PDR) at Baseline Who Developed High-Risk PDR at Week 52, ITT and Treatment-Naive Populations
The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced PDR. High-risk PDR was defined as an ETDRS DRSS score of ≥71 on the 7-field/4-wide field color fundus photographs assessment by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% CI is a rounding of 95.04% CI.
Time frame: Baseline and Week 52
Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 52, ITT Population
Time frame: Week 52
Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 52, Treatment-Naive Population
Time frame: Week 52
Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 96, ITT Population
Time frame: Week 96
Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 96, Treatment-Naive Population
Time frame: Week 96
Percentage of Participants in the Faricimab 6 mg PTI Arm at Week 52 Who Achieved a Once Every 12-Weeks or 16-Weeks Treatment Interval Without an Interval Decrease Below Once Every 12 Weeks, ITT and Treatment-Naive Populations
Time frame: From start of PTI (Week 12 or later) until Week 52
Percentage of Participants in the Faricimab 6 mg PTI Arm at Week 96 Who Achieved a Once Every 12-Weeks or 16-Weeks Treatment Interval Without an Interval Decrease Below Once Every 12 Weeks, ITT and Treatment-Naive Populations
Time frame: From start of PTI (Week 12 or later) until Week 96
Change From Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations
Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment (U.S. and Canada vs. the rest of the world; Asia and rest of the world regions were combined). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: From Baseline through Week 56
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population
Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment (U.S. and Canada vs. the rest of the world; Asia and rest of the world regions were combined). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population
Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (\<64 vs. ≥64 letters), and region of enrollment (U.S. and Canada vs. the rest of the world; Asia and rest of the world regions were combined). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations
Absence of diabetic macular edema was defined as achieving a central subfield thickness (CST) of \<325 microns in the study eye. CST was defined as the distance between the internal limiting membrane and Bruch's membrane. For each participant, an average CST value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Average of Weeks 48, 52, and 56
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population
Absence of diabetic macular edema was defined as achieving a central subfield thickness of \<325 microns in the study eye. Central subfield thickness was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population
Retinal dryness was defined as achieving a central subfield thickness (ILM-BM) of \<280 microns. Central subfield thickness was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. The weighted estimates of the percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye Over Time, ITT Population
Intraretinal fluid was measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world); Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 16, 48, 52, 56, 92, 96, and 100
Percentage of Participants With Absence of Subretinal Fluid in the Study Eye Over Time, ITT Population
Subretinal fluid was measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world); Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 16, 48, 52, 56, 92, 96, and 100
Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye Over Time, ITT Population
Intraretinal fluid and subretinal fluid were measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world); Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 16, 48, 52, 56, 92, 96, and 100
Change From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) Composite Score Over Time, ITT Population
The NEI VFQ-25 captures a patient's perception of vision-related functioning and quality of life. The core measure includes 25 items that comprise 11 vision-related subscales and one item on general health. The composite score ranges from 0 to 100, with higher scores, or a positive change from baseline, indicating better vision-related functioning. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline NEI VFQ-25 Composite Score (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% CI is a rounding of 95.04% CI.
Time frame: Baseline, Weeks 24, 52, and 100
Percentage of Participants With at Least One Adverse Event
This analysis of adverse events (AEs) includes both ocular and non-ocular (systemic) AEs. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. AEs of special interest included the following: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law; Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation.
Time frame: From first dose of study drug through end of study (up to 2 years)
Percentage of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye
This analysis of adverse events (AEs) only includes ocular AEs, which are categorized as having occurred either in the study eye or the fellow eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. Ocular AEs of special interest included the following: Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation.
Time frame: From first dose of study drug through end of study (up to 2 years)
Percentage of Participants With at Least One Non-Ocular Adverse Event
This analysis of adverse events (AEs) only includes non-ocular (systemic) AEs. Investigators sought information on adverse events (AEs) at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. The non-ocular AE of special interest was: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.
Time frame: From first dose of study drug through end of study (up to 2 years)
Plasma Concentration of Faricimab Over Time
Faricimab concentration in plasma was determined using a validated immunoassay method.
Time frame: Pre-dose on Day 1 (Baseline); Weeks 4, 28, 52, 76, and 100
Percentage of Participants Who Test Positive for Treatment-Emergent Anti-Drug Antibodies Against Faricimab During the Study
Anti-drug antibodies (ADAs) against fariciamb were detected in plasma using a validated bridging enzyme-linked immunosorbent assay (ELISA). The percentage of participants with treatment-emergent ADA-positive samples includes post-baseline evaluable participants with at least one treatment-induced (defined as having an ADA-negative sample or missing sample at baseline and any positive post-baseline sample) or treatment-boosted (defined as having an ADA-positive sample at baseline and any positive post-baseline sample with a titer that is equal to or greater than 4-fold baseline titer) ADA-positive sample during the study treatment period.
Time frame: Baseline, Weeks 4, 28, 52, 76, and 100
| Milestone | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Started | 315 | 313 | 312 |
| Received at least one dose of study drug | 313 | 313 | 311 |
| Completed up to week 56 | 291 | 289 | 292 |
| Completed | 263 | 269 | 260 |
| Not completed | 52 | 44 | 52 |
| Withdrew: Death | 16 | 21 | 13 |
| Withdrew: Adverse event | 6 | 6 | 5 |
| Withdrew: Withdrawal by subject | 12 | 7 | 19 |
| Withdrew: Lost to follow-up | 12 | 9 | 9 |
| Withdrew: Protocol violation | 1 | 0 | 1 |
| Withdrew: Physician decision | 3 | 0 | 1 |
| Withdrew: Pregnancy | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 |
| Withdrew: Other | 2 | 0 | 3 |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded. 97.5% CI is a rounding of 97.52% CI.
| ETDRS Letters | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| ITT Population | 10.7 (9.4 to 12.0) | 11.6 (10.3 to 12.9) | 10.9 (9.6 to 12.2) |
| Treatment-Naive Population | 10.6 (9.1 to 12.1) | 11.4 (9.9 to 12.8) | 11.3 (9.8 to 12.8) |
The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 97.5% confidence interval (CI) is a rounding of 97.52% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| ITT Population | 46.0 (38.8 to 53.1) | 42.5 (35.5 to 49.5) | 35.8 (29.1 to 42.5) |
| Treatment-Naive Population | 49.7 (41.2 to 58.2) | 47.6 (39.5 to 55.8) | 42.5 (34.4 to 50.6) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded. 95% CI is a rounding of 95.04% CI.
| ETDRS Letters | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 4 | 5.5 (4.8 to 6.3) | 6.7 (6.0 to 7.4) | 6.5 (5.8 to 7.2) |
| Week 8 | 7.2 (6.4 to 7.9) | 8.2 (7.4 to 9.0) | 8.1 (7.3 to 8.8) |
| Week 12 | 8.2 (7.4 to 9.0) | 9.2 (8.4 to 10.0) | 9.1 (8.3 to 9.9) |
| Week 16 | 9.1 (8.2 to 9.9) | 10.0 (9.2 to 10.8) | 9.7 (8.8 to 10.5) |
| Week 20 | 9.6 (8.7 to 10.5) | 9.9 (9.0 to 10.8) | 9.8 (8.9 to 10.7) |
| Week 24 | 10.2 (9.3 to 11.1) | 11.3 (10.4 to 12.2) | 9.4 (8.5 to 10.3) |
| Week 28 | 9.5 (8.6 to 10.5) | 11.0 (10.0 to 11.9) | 10.5 (9.6 to 11.5) |
| Week 32 | 10.2 (9.2 to 11.2) | 10.9 (9.9 to 11.9) | 10.2 (9.2 to 11.2) |
| Week 36 | 10.1 (9.1 to 11.1) | 11.7 (10.7 to 12.8) | 10.4 (9.4 to 11.4) |
| Week 40 | 10.2 (9.1 to 11.2) | 11.4 (10.3 to 12.5) | 10.3 (9.2 to 11.4) |
| Week 44 | 9.9 (8.8 to 11.0) | 11.4 (10.3 to 12.5) | 10.7 (9.6 to 11.9) |
| Week 48 | 10.5 (9.4 to 11.6) | 11.4 (10.3 to 12.5) | 10.8 (9.7 to 11.9) |
| Week 52 | 9.9 (8.7 to 11.1) | 11.0 (9.8 to 12.2) | 10.9 (9.7 to 12.2) |
| Week 56 | 10.8 (9.7 to 12.0) | 11.6 (10.4 to 12.8) | 10.6 (9.4 to 11.8) |
| Week 60 | 10.3 (9.1 to 11.5) | 12.0 (10.8 to 13.1) | 11.3 (10.1 to 12.5) |
| Week 64 | 10.7 (9.5 to 12.0) | 11.5 (10.3 to 12.7) | 10.8 (9.6 to 12.0) |
| Week 68 | 10.2 (8.9 to 11.5) | 11.4 (10.1 to 12.6) | 11.3 (10.0 to 12.5) |
| Week 72 | 10.4 (9.1 to 11.7) | 11.3 (10.0 to 12.6) | 10.7 (9.4 to 12.0) |
| Week 76 | 10.2 (8.8 to 11.6) | 11.5 (10.1 to 12.9) | 11.0 (9.6 to 12.4) |
| Week 80 | 10.9 (9.5 to 12.2) | 11.1 (9.8 to 12.4) | 10.9 (9.6 to 12.2) |
| Week 84 | 9.9 (8.6 to 11.2) | 11.5 (10.2 to 12.8) | 11.8 (10.5 to 13.1) |
| Week 88 | 9.8 (8.4 to 11.2) | 10.9 (9.5 to 12.3) | 11.0 (9.6 to 12.4) |
| Week 92 | 10.5 (9.1 to 11.9) | 11.2 (9.9 to 12.6) | 11.5 (10.1 to 12.9) |
| Week 96 | 11.1 (9.7 to 12.6) | 10.6 (9.2 to 12.0) | 11.1 (9.7 to 12.5) |
| Week 100 | 10.5 (9.1 to 12.0) | 10.4 (9.0 to 11.8) | 11.6 (10.1 to 13.1) |
Best-Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline BCVA (continuous), baseline BCVA (\<64 vs. ≥64 letters), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
| ETDRS Letters | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 4 | 5.8 (5.0 to 6.7) | 6.8 (6.0 to 7.6) | 6.9 (6.1 to 7.7) |
| Week 8 | 7.2 (6.3 to 8.1) | 8.3 (7.4 to 9.2) | 8.7 (7.8 to 9.5) |
| Week 12 | 8.5 (7.6 to 9.4) | 9.3 (8.4 to 10.2) | 9.6 (8.7 to 10.5) |
| Week 16 | 9.3 (8.4 to 10.3) | 10.0 (9.1 to 10.9) | 10.1 (9.2 to 11.1) |
| Week 20 | 9.7 (8.7 to 10.8) | 9.7 (8.6 to 10.7) | 10.3 (9.3 to 11.4) |
| Week 24 | 10.5 (9.4 to 11.5) | 11.2 (10.2 to 12.2) | 9.8 (8.7 to 10.8) |
| Week 28 | 9.6 (8.5 to 10.7) | 11.0 (9.9 to 12.1) | 11.0 (9.9 to 12.1) |
| Week 32 | 10.3 (9.1 to 11.5) | 10.9 (9.8 to 12.1) | 10.6 (9.5 to 11.8) |
| Week 36 | 10.3 (9.1 to 11.6) | 11.9 (10.7 to 13.1) | 10.6 (9.4 to 11.8) |
| Week 40 | 10.0 (8.7 to 11.3) | 11.4 (10.1 to 12.7) | 10.7 (9.4 to 12.1) |
| Week 44 | 10.1 (8.8 to 11.4) | 11.4 (10.1 to 12.7) | 11.3 (10.0 to 12.6) |
| Week 48 | 10.3 (9.0 to 11.7) | 11.0 (9.7 to 12.4) | 11.2 (9.8 to 12.5) |
| Week 52 | 9.6 (8.2 to 11.1) | 10.7 (9.3 to 12.2) | 11.3 (9.9 to 12.8) |
| Week 56 | 10.9 (9.5 to 12.3) | 11.5 (10.1 to 12.8) | 11.0 (9.6 to 12.4) |
| Week 60 | 10.1 (8.7 to 11.6) | 12.0 (10.6 to 13.4) | 11.6 (10.2 to 13.0) |
| Week 64 | 10.6 (9.1 to 12.1) | 11.5 (10.0 to 13.0) | 11.0 (9.5 to 12.4) |
| Week 68 | 10.3 (8.8 to 11.8) | 11.3 (9.8 to 12.8) | 11.4 (9.9 to 12.9) |
| Week 72 | 10.2 (8.6 to 11.7) | 11.3 (9.8 to 12.8) | 10.8 (9.3 to 12.4) |
| Week 76 | 9.9 (8.2 to 11.6) | 11.4 (9.7 to 13.0) | 10.8 (9.2 to 12.5) |
| Week 80 | 10.6 (9.0 to 12.2) | 11.0 (9.4 to 12.6) | 11.1 (9.6 to 12.7) |
| Week 84 | 9.6 (8.0 to 11.1) | 11.6 (10.0 to 13.1) | 11.9 (10.3 to 13.4) |
| Week 88 | 9.4 (7.7 to 11.1) | 10.8 (9.1 to 12.5) | 10.9 (9.2 to 12.6) |
| Week 92 | 10.1 (8.4 to 11.7) | 11.2 (9.5 to 12.8) | 11.6 (10.0 to 13.3) |
| Week 96 | 11.1 (9.4 to 12.8) | 10.5 (8.9 to 12.1) | 11.4 (9.7 to 13.0) |
| Week 100 | 10.5 (8.8 to 12.3) | 10.5 (8.8 to 12.1) | 11.7 (10.0 to 13.4) |
BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Gaining ≥15 Letters | 29.2 (23.9 to 34.5) | 35.5 (30.1 to 40.9) | 31.8 (26.6 to 37.0) |
| Gaining ≥10 Letters | 57.2 (51.3 to 63.1) | 58.3 (52.6 to 64.0) | 57.6 (51.8 to 63.4) |
| Gaining ≥5 Letters | 78.9 (74.1 to 83.8) | 79.6 (74.9 to 84.3) | 81.4 (76.9 to 86.0) |
| Gaining ≥0 Letters | 91.5 (88.1 to 94.8) | 94.5 (91.8 to 97.2) | 91.4 (88.1 to 94.6) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 4 | 7.7 (4.8 to 10.7) | 13.0 (9.4 to 16.6) | 11.4 (8.0 to 14.9) |
| Week 8 | 13.4 (9.6 to 17.1) | 18.8 (14.8 to 22.9) | 16.7 (12.7 to 20.7) |
| Week 12 | 14.9 (11.0 to 18.9) | 23.1 (18.6 to 27.5) | 22.1 (17.6 to 26.5) |
| Week 16 | 20.4 (15.9 to 24.9) | 27.8 (22.9 to 32.7) | 22.2 (17.7 to 26.8) |
| Week 20 | 25.6 (20.8 to 30.5) | 28.4 (23.4 to 33.4) | 24.0 (19.4 to 28.6) |
| Week 24 | 26.8 (21.8 to 31.8) | 34.2 (29.0 to 39.3) | 25.7 (21.0 to 30.5) |
| Week 28 | 23.5 (18.6 to 28.4) | 31.2 (26.2 to 36.3) | 29.2 (24.3 to 34.2) |
| Week 32 | 28.5 (23.1 to 33.8) | 36.2 (30.7 to 41.7) | 25.8 (21.0 to 30.7) |
| Week 36 | 24.4 (19.3 to 29.5) | 40.2 (34.6 to 45.8) | 32.5 (27.1 to 37.9) |
| Week 40 | 29.7 (24.3 to 35.1) | 37.1 (31.6 to 42.7) | 30.3 (24.9 to 35.6) |
| Week 44 | 29.2 (23.8 to 34.6) | 37.1 (31.7 to 42.6) | 34.9 (29.4 to 40.4) |
| Week 48 | 31.7 (26.1 to 37.2) | 39.6 (33.9 to 45.3) | 34.0 (28.7 to 39.3) |
| Week 52 | 31.2 (25.7 to 36.8) | 37.2 (31.7 to 42.7) | 36.0 (30.3 to 41.6) |
| Week 56 | 38.1 (32.3 to 43.9) | 38.4 (32.7 to 44.0) | 31.5 (26.1 to 36.9) |
| Week 60 | 34.4 (28.8 to 40.0) | 41.3 (35.5 to 47.1) | 35.9 (30.3 to 41.4) |
| Week 64 | 37.5 (31.7 to 43.4) | 41.4 (35.8 to 47.1) | 34.8 (29.1 to 40.5) |
| Week 68 | 37.1 (31.4 to 42.9) | 43.7 (37.9 to 49.6) | 37.1 (31.4 to 42.8) |
| Week 72 | 34.8 (29.1 to 40.6) | 38.2 (32.6 to 43.8) | 35.2 (29.5 to 41.0) |
| Week 76 | 36.6 (30.7 to 42.6) | 44.1 (38.4 to 49.9) | 37.2 (31.3 to 43.1) |
| Week 80 | 39.3 (33.4 to 45.3) | 42.1 (36.5 to 47.8) | 36.9 (31.1 to 42.6) |
| Week 84 | 40.6 (34.5 to 46.6) | 41.5 (35.8 to 47.2) | 38.8 (32.9 to 44.6) |
| Week 88 | 39.2 (33.2 to 45.2) | 39.8 (34.2 to 45.4) | 35.9 (30.1 to 41.6) |
| Week 92 | 39.7 (33.8 to 45.7) | 41.0 (35.3 to 46.6) | 38.8 (33.0 to 44.7) |
| Week 96 | 41.3 (35.1 to 47.4) | 40.2 (34.5 to 45.8) | 38.8 (32.9 to 44.7) |
| Week 100 | 40.2 (34.2 to 46.1) | 40.3 (34.7 to 46.0) | 40.9 (34.9 to 46.9) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 4 | 23.9 (19.2 to 28.6) | 31.1 (26.2 to 36.1) | 27.1 (22.2 to 32.0) |
| Week 8 | 30.8 (25.7 to 35.9) | 37.1 (31.8 to 42.3) | 41.0 (35.6 to 46.4) |
| Week 12 | 35.5 (30.2 to 40.8) | 47.5 (42.0 to 53.0) | 46.2 (40.7 to 51.7) |
| Week 16 | 43.7 (38.0 to 49.3) | 48.4 (42.8 to 54.0) | 49.7 (44.1 to 55.3) |
| Week 20 | 45.6 (40.0 to 51.3) | 53.1 (47.6 to 58.6) | 50.3 (44.7 to 56.0) |
| Week 24 | 55.6 (50.0 to 61.2) | 58.6 (53.2 to 64.1) | 48.2 (42.6 to 53.9) |
| Week 28 | 55.6 (49.9 to 61.3) | 57.0 (51.4 to 62.6) | 57.2 (51.6 to 62.9) |
| Week 32 | 56.7 (50.9 to 62.6) | 58.5 (52.8 to 64.2) | 53.1 (47.3 to 58.8) |
| Week 36 | 55.6 (49.7 to 61.5) | 65.5 (60.0 to 71.1) | 55.7 (49.9 to 61.6) |
| Week 40 | 55.7 (49.8 to 61.5) | 60.0 (54.2 to 65.8) | 53.2 (47.2 to 59.2) |
| Week 44 | 55.1 (49.3 to 61.0) | 60.5 (54.7 to 66.2) | 57.2 (51.3 to 63.2) |
| Week 48 | 57.0 (51.0 to 62.9) | 60.2 (54.5 to 65.9) | 61.7 (55.9 to 67.4) |
| Week 52 | 59.9 (54.0 to 65.8) | 59.5 (53.8 to 65.2) | 60.2 (54.3 to 66.2) |
| Week 56 | 63.5 (57.7 to 69.4) | 62.6 (56.9 to 68.3) | 59.0 (53.0 to 64.9) |
| Week 60 | 59.4 (53.5 to 65.2) | 62.6 (56.9 to 68.3) | 60.7 (54.9 to 66.5) |
| Week 64 | 64.9 (59.2 to 70.7) | 60.0 (54.3 to 65.7) | 59.6 (53.8 to 65.5) |
| Week 68 | 60.1 (54.2 to 66.0) | 58.9 (53.1 to 64.7) | 59.4 (53.5 to 65.4) |
| Week 72 | 61.2 (55.2 to 67.1) | 61.0 (55.2 to 66.8) | 56.8 (50.7 to 62.9) |
| Week 76 | 60.1 (54.1 to 66.2) | 67.8 (62.3 to 73.3) | 64.2 (58.3 to 70.0) |
| Week 80 | 64.0 (58.1 to 70.0) | 61.7 (56.1 to 67.4) | 60.5 (54.5 to 66.4) |
| Week 84 | 61.0 (55.0 to 67.0) | 64.4 (58.8 to 70.1) | 64.4 (58.6 to 70.2) |
| Week 88 | 59.6 (53.5 to 65.7) | 59.8 (54.0 to 65.7) | 62.7 (56.9 to 68.5) |
| Week 92 | 63.2 (57.3 to 69.1) | 63.3 (57.6 to 69.0) | 64.6 (58.7 to 70.4) |
| Week 96 | 60.3 (54.1 to 66.4) | 59.7 (53.9 to 65.5) | 62.5 (56.5 to 68.6) |
| Week 100 | 63.0 (57.3 to 68.8) | 60.5 (54.8 to 66.2) | 66.0 (60.1 to 71.8) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 4 | 53.6 (48.1 to 59.1) | 62.6 (57.3 to 67.9) | 61.1 (55.7 to 66.5) |
| Week 8 | 64.7 (59.4 to 70.0) | 71.1 (66.1 to 76.0) | 67.6 (62.4 to 72.8) |
| Week 12 | 71.9 (66.9 to 76.9) | 74.3 (69.4 to 79.2) | 75.4 (70.6 to 80.3) |
| Week 16 | 74.9 (70.0 to 79.9) | 81.4 (77.0 to 85.8) | 77.5 (72.7 to 82.2) |
| Week 20 | 78.2 (73.6 to 82.9) | 78.4 (73.7 to 83.1) | 76.4 (71.6 to 81.1) |
| Week 24 | 80.5 (76.0 to 85.0) | 83.3 (79.0 to 87.5) | 71.0 (65.8 to 76.1) |
| Week 28 | 77.4 (72.5 to 82.2) | 81.0 (76.6 to 85.5) | 79.1 (74.4 to 83.8) |
| Week 32 | 79.4 (74.6 to 84.3) | 77.1 (72.2 to 82.0) | 81.3 (76.8 to 85.8) |
| Week 36 | 79.2 (74.4 to 84.1) | 82.6 (78.2 to 87.1) | 78.3 (73.5 to 83.1) |
| Week 40 | 76.3 (71.3 to 81.3) | 84.3 (80.0 to 88.6) | 77.1 (72.0 to 82.2) |
| Week 44 | 80.7 (75.9 to 85.4) | 81.9 (77.3 to 86.4) | 77.9 (73.0 to 82.7) |
| Week 48 | 79.2 (74.4 to 84.1) | 82.0 (77.5 to 86.6) | 79.3 (74.4 to 84.1) |
| Week 52 | 78.4 (73.5 to 83.4) | 78.4 (73.5 to 83.2) | 81.2 (76.4 to 85.9) |
| Week 56 | 83.0 (78.5 to 87.6) | 81.3 (76.6 to 86.0) | 81.4 (76.7 to 86.1) |
| Week 60 | 80.4 (75.7 to 85.1) | 81.3 (76.7 to 85.9) | 81.4 (76.8 to 86.1) |
| Week 64 | 80.2 (75.4 to 85.1) | 80.6 (75.9 to 85.2) | 79.7 (74.9 to 84.5) |
| Week 68 | 79.1 (74.1 to 84.0) | 78.9 (74.0 to 83.8) | 79.1 (74.2 to 84.0) |
| Week 72 | 79.7 (74.8 to 84.6) | 78.1 (73.2 to 83.0) | 80.9 (76.1 to 85.7) |
| Week 76 | 79.9 (74.9 to 84.8) | 78.9 (74.0 to 83.8) | 82.9 (78.3 to 87.5) |
| Week 80 | 81.0 (76.1 to 85.9) | 80.3 (75.5 to 85.0) | 78.3 (73.2 to 83.4) |
| Week 84 | 77.1 (71.9 to 82.3) | 82.0 (77.5 to 86.5) | 82.6 (77.9 to 87.2) |
| Week 88 | 79.3 (74.2 to 84.3) | 80.5 (75.8 to 85.2) | 80.5 (75.6 to 85.5) |
| Week 92 | 81.4 (76.6 to 86.3) | 82.1 (77.5 to 86.7) | 83.2 (78.6 to 87.7) |
| Week 96 | 82.6 (77.8 to 87.3) | 77.4 (72.5 to 82.4) | 81.2 (76.3 to 86.0) |
| Week 100 | 81.1 (76.3 to 85.9) | 77.0 (71.9 to 82.0) | 85.2 (80.9 to 89.6) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 4 | 86.1 (82.3 to 90.0) | 90.8 (87.7 to 94.0) | 88.9 (85.4 to 92.3) |
| Week 8 | 89.7 (86.4 to 93.0) | 91.9 (88.8 to 94.9) | 91.1 (87.9 to 94.2) |
| Week 12 | 92.5 (89.6 to 95.4) | 94.7 (92.2 to 97.2) | 92.7 (89.8 to 95.6) |
| Week 16 | 91.2 (88.0 to 94.4) | 94.9 (92.4 to 97.4) | 93.7 (90.9 to 96.4) |
| Week 20 | 93.9 (91.2 to 96.6) | 93.1 (90.2 to 96.0) | 92.2 (89.2 to 95.2) |
| Week 24 | 93.1 (90.2 to 96.0) | 93.8 (91.0 to 96.5) | 89.9 (86.5 to 93.3) |
| Week 28 | 90.4 (87.0 to 93.8) | 94.1 (91.4 to 96.8) | 91.5 (88.3 to 94.6) |
| Week 32 | 92.1 (88.9 to 95.3) | 95.1 (92.6 to 97.7) | 91.3 (88.0 to 94.6) |
| Week 36 | 92.1 (88.9 to 95.3) | 93.2 (90.2 to 96.2) | 90.4 (87.0 to 93.9) |
| Week 40 | 90.9 (87.5 to 94.3) | 94.0 (91.1 to 96.8) | 93.2 (90.2 to 96.2) |
| Week 44 | 91.0 (87.6 to 94.4) | 94.5 (91.8 to 97.2) | 91.0 (87.6 to 94.4) |
| Week 48 | 95.2 (92.6 to 97.7) | 93.7 (90.8 to 96.5) | 91.3 (88.0 to 94.6) |
| Week 52 | 89.8 (86.1 to 93.4) | 91.3 (88.0 to 94.7) | 91.0 (87.5 to 94.5) |
| Week 56 | 91.4 (88.0 to 94.8) | 93.9 (91.0 to 96.7) | 90.6 (87.1 to 94.2) |
| Week 60 | 89.5 (85.9 to 93.2) | 93.5 (90.5 to 96.4) | 92.8 (89.7 to 95.9) |
| Week 64 | 91.3 (87.9 to 94.7) | 92.7 (89.6 to 95.8) | 92.0 (88.7 to 95.2) |
| Week 68 | 92.1 (88.8 to 95.4) | 92.9 (89.8 to 96.0) | 91.9 (88.6 to 95.2) |
| Week 72 | 88.5 (84.6 to 92.5) | 91.9 (88.7 to 95.2) | 90.0 (86.3 to 93.7) |
| Week 76 | 87.8 (83.8 to 91.9) | 91.2 (87.8 to 94.7) | 92.5 (89.4 to 95.7) |
| Week 80 | 89.2 (85.4 to 93.0) | 91.5 (88.1 to 94.9) | 89.6 (85.9 to 93.4) |
| Week 84 | 87.1 (82.9 to 91.2) | 92.4 (89.2 to 95.6) | 93.5 (90.5 to 96.5) |
| Week 88 | 87.3 (83.2 to 91.4) | 90.3 (86.7 to 93.8) | 89.9 (86.1 to 93.7) |
| Week 92 | 89.4 (85.5 to 93.2) | 91.1 (87.6 to 94.6) | 90.8 (87.3 to 94.3) |
| Week 96 | 90.7 (87.0 to 94.4) | 88.9 (85.1 to 92.6) | 90.5 (86.8 to 94.2) |
| Week 100 | 88.3 (84.3 to 92.3) | 86.8 (82.7 to 90.9) | 92.0 (88.7 to 95.4) |
BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Gaining ≥15 Letters | 28.6 (22.3 to 34.8) | 35.5 (29.3 to 41.7) | 33.8 (27.7 to 39.9) |
| Gaining ≥10 Letters | 57.5 (50.7 to 64.4) | 59.6 (53.2 to 65.9) | 57.5 (50.9 to 64.1) |
| Gaining ≥5 Letters | 80.0 (74.4 to 85.5) | 77.2 (71.6 to 82.8) | 84.5 (79.6 to 89.3) |
| Gaining ≥0 Letters | 91.5 (87.6 to 95.3) | 93.5 (90.2 to 96.8) | 91.6 (87.9 to 95.3) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 4 | 8.9 (5.3 to 12.5) | 14.9 (10.6 to 19.3) | 12.7 (8.6 to 16.9) |
| Week 8 | 14.3 (9.9 to 18.8) | 19.2 (14.6 to 23.8) | 17.8 (13.1 to 22.6) |
| Week 12 | 15.7 (11.1 to 20.3) | 22.2 (17.2 to 27.1) | 24.2 (19.0 to 29.5) |
| Week 16 | 21.3 (16.0 to 26.6) | 28.2 (22.6 to 33.8) | 24.0 (18.6 to 29.3) |
| Week 20 | 26.5 (20.8 to 32.2) | 27.7 (22.2 to 33.3) | 26.2 (20.7 to 31.6) |
| Week 24 | 27.1 (21.3 to 32.9) | 34.3 (28.4 to 40.2) | 27.5 (22.0 to 33.1) |
| Week 28 | 21.5 (16.0 to 27.0) | 30.7 (25.0 to 36.4) | 32.8 (26.8 to 38.7) |
| Week 32 | 27.2 (21.0 to 33.5) | 37.5 (31.2 to 43.8) | 29.5 (23.6 to 35.4) |
| Week 36 | 23.5 (17.6 to 29.5) | 41.9 (35.5 to 48.2) | 34.9 (28.6 to 41.2) |
| Week 40 | 27.6 (21.5 to 33.8) | 37.7 (31.2 to 44.1) | 33.5 (27.0 to 39.9) |
| Week 44 | 27.2 (21.1 to 33.4) | 39.7 (33.3 to 46.0) | 37.0 (30.6 to 43.4) |
| Week 48 | 32.5 (26.0 to 39.1) | 39.6 (33.1 to 46.0) | 36.3 (30.1 to 42.5) |
| Week 52 | 30.7 (24.3 to 37.1) | 35.9 (29.6 to 42.1) | 37.4 (30.9 to 43.9) |
| Week 56 | 37.7 (31.0 to 44.5) | 38.8 (32.3 to 45.2) | 34.3 (27.9 to 40.8) |
| Week 60 | 33.1 (26.6 to 39.6) | 42.2 (35.6 to 48.9) | 38.9 (32.4 to 45.5) |
| Week 64 | 37.9 (31.1 to 44.7) | 43.5 (37.0 to 50.0) | 36.0 (29.5 to 42.6) |
| Week 68 | 37.4 (30.7 to 44.2) | 45.4 (38.7 to 52.1) | 39.0 (32.4 to 45.5) |
| Week 72 | 35.6 (28.8 to 42.4) | 39.6 (33.1 to 46.0) | 36.6 (29.8 to 43.3) |
| Week 76 | 37.6 (30.6 to 44.6) | 45.3 (38.8 to 51.8) | 37.2 (30.5 to 43.9) |
| Week 80 | 39.7 (32.7 to 46.8) | 43.2 (36.8 to 49.7) | 40.5 (33.6 to 47.3) |
| Week 84 | 40.7 (33.7 to 47.8) | 43.2 (36.8 to 49.7) | 41.2 (34.3 to 48.1) |
| Week 88 | 39.1 (32.1 to 46.2) | 40.7 (34.4 to 47.1) | 38.0 (31.2 to 44.8) |
| Week 92 | 40.2 (33.2 to 47.3) | 42.1 (35.7 to 48.5) | 40.4 (33.6 to 47.3) |
| Week 96 | 42.9 (35.6 to 50.2) | 41.2 (34.9 to 47.6) | 40.1 (33.2 to 47.0) |
| Week 100 | 41.7 (34.6 to 48.7) | 42.5 (36.1 to 48.9) | 41.2 (34.3 to 48.1) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 4 | 25.2 (19.7 to 30.7) | 32.0 (26.3 to 37.7) | 29.2 (23.5 to 35.0) |
| Week 8 | 31.1 (25.2 to 37.1) | 37.2 (31.3 to 43.1) | 43.9 (37.7 to 50.2) |
| Week 12 | 36.9 (30.8 to 43.1) | 46.5 (40.3 to 52.6) | 48.9 (42.6 to 55.2) |
| Week 16 | 43.8 (37.3 to 50.3) | 47.8 (41.4 to 54.1) | 49.8 (43.5 to 56.2) |
| Week 20 | 44.9 (38.4 to 51.4) | 53.7 (47.5 to 59.9) | 51.5 (45.1 to 57.9) |
| Week 24 | 57.6 (51.1 to 64.1) | 57.9 (51.7 to 64.2) | 49.9 (43.5 to 56.3) |
| Week 28 | 55.3 (48.6 to 61.9) | 56.6 (50.3 to 62.9) | 57.4 (50.8 to 63.9) |
| Week 32 | 59.0 (52.2 to 65.9) | 59.6 (53.1 to 66.0) | 53.1 (46.5 to 59.7) |
| Week 36 | 59.0 (52.1 to 65.9) | 66.3 (60.0 to 72.5) | 55.8 (49.1 to 62.5) |
| Week 40 | 55.5 (48.7 to 62.4) | 59.7 (53.1 to 66.4) | 54.5 (47.7 to 61.4) |
| Week 44 | 55.0 (48.1 to 61.9) | 59.2 (52.7 to 65.7) | 58.1 (51.3 to 64.8) |
| Week 48 | 57.1 (50.2 to 64.0) | 58.5 (52.0 to 65.0) | 62.6 (56.0 to 69.2) |
| Week 52 | 60.0 (53.1 to 66.8) | 58.8 (52.2 to 65.3) | 61.0 (54.2 to 67.8) |
| Week 56 | 65.0 (58.3 to 71.7) | 62.9 (56.5 to 69.3) | 60.1 (53.4 to 66.8) |
| Week 60 | 61.5 (54.7 to 68.2) | 63.4 (56.9 to 69.9) | 61.3 (54.5 to 68.0) |
| Week 64 | 67.7 (61.1 to 74.3) | 59.8 (53.3 to 66.2) | 59.7 (53.0 to 66.4) |
| Week 68 | 64.1 (57.4 to 70.8) | 60.7 (54.2 to 67.2) | 60.6 (53.9 to 67.3) |
| Week 72 | 62.6 (55.8 to 69.5) | 62.5 (56.0 to 69.0) | 56.7 (49.8 to 63.7) |
| Week 76 | 61.8 (54.8 to 68.9) | 66.8 (60.5 to 73.0) | 66.2 (59.6 to 72.9) |
| Week 80 | 66.7 (59.8 to 73.5) | 62.4 (56.0 to 68.8) | 62.8 (56.0 to 69.6) |
| Week 84 | 63.2 (56.3 to 70.1) | 65.3 (59.0 to 71.6) | 67.1 (60.5 to 73.6) |
| Week 88 | 60.2 (53.2 to 67.3) | 60.9 (54.3 to 67.6) | 61.9 (55.1 to 68.7) |
| Week 92 | 63.2 (56.2 to 70.2) | 65.1 (58.7 to 71.5) | 65.0 (58.2 to 71.7) |
| Week 96 | 58.8 (51.5 to 66.0) | 60.6 (54.0 to 67.1) | 63.8 (56.9 to 70.6) |
| Week 100 | 64.0 (57.3 to 70.7) | 62.4 (56.0 to 68.8) | 64.8 (58.0 to 71.6) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 4 | 53.8 (47.5 to 60.2) | 63.1 (57.1 to 69.1) | 62.8 (56.7 to 68.9) |
| Week 8 | 63.4 (57.2 to 69.6) | 70.5 (64.8 to 76.2) | 70.4 (64.6 to 76.2) |
| Week 12 | 72.7 (66.9 to 78.4) | 75.4 (69.9 to 80.8) | 77.0 (71.6 to 82.4) |
| Week 16 | 75.6 (70.0 to 81.3) | 81.3 (76.3 to 86.3) | 79.3 (74.1 to 84.5) |
| Week 20 | 79.0 (73.6 to 84.3) | 79.3 (74.0 to 84.6) | 78.2 (72.9 to 83.5) |
| Week 24 | 81.7 (76.6 to 86.8) | 82.9 (78.1 to 87.7) | 71.4 (65.5 to 77.2) |
| Week 28 | 76.9 (71.2 to 82.5) | 81.7 (76.6 to 86.7) | 80.0 (74.8 to 85.3) |
| Week 32 | 80.0 (74.4 to 85.6) | 77.6 (72.0 to 83.1) | 83.7 (78.8 to 88.7) |
| Week 36 | 80.5 (74.9 to 86.1) | 82.9 (77.9 to 88.0) | 79.6 (74.1 to 85.1) |
| Week 40 | 77.1 (71.3 to 82.8) | 85.3 (80.5 to 90.1) | 80.0 (74.5 to 85.6) |
| Week 44 | 81.4 (76.0 to 86.8) | 82.5 (77.4 to 87.6) | 80.8 (75.4 to 86.2) |
| Week 48 | 79.5 (73.8 to 85.2) | 80.0 (74.6 to 85.4) | 80.8 (75.4 to 86.2) |
| Week 52 | 78.7 (72.9 to 84.4) | 75.3 (69.5 to 81.1) | 82.3 (77.1 to 87.6) |
| Week 56 | 84.0 (78.9 to 89.2) | 81.2 (75.9 to 86.4) | 81.9 (76.6 to 87.1) |
| Week 60 | 81.0 (75.5 to 86.4) | 80.5 (75.2 to 85.8) | 80.0 (74.5 to 85.5) |
| Week 64 | 80.7 (75.1 to 86.3) | 80.2 (74.9 to 85.6) | 80.3 (74.8 to 85.7) |
| Week 68 | 82.0 (76.5 to 87.5) | 78.3 (72.6 to 83.9) | 79.7 (74.1 to 85.2) |
| Week 72 | 81.5 (76.0 to 87.0) | 77.3 (71.6 to 82.9) | 80.9 (75.4 to 86.5) |
| Week 76 | 79.5 (73.7 to 85.4) | 78.0 (72.4 to 83.6) | 83.8 (78.6 to 88.9) |
| Week 80 | 82.0 (76.3 to 87.7) | 80.5 (75.2 to 85.8) | 80.0 (74.3 to 85.7) |
| Week 84 | 78.6 (72.6 to 84.6) | 83.0 (78.0 to 87.9) | 81.8 (76.4 to 87.3) |
| Week 88 | 77.9 (71.8 to 83.9) | 80.7 (75.4 to 86.1) | 80.6 (74.9 to 86.2) |
| Week 92 | 80.5 (74.8 to 86.3) | 82.1 (76.8 to 87.3) | 82.5 (77.2 to 87.9) |
| Week 96 | 82.7 (77.1 to 88.3) | 76.9 (71.2 to 82.5) | 82.4 (76.9 to 87.8) |
| Week 100 | 80.0 (74.3 to 85.8) | 78.2 (72.6 to 83.9) | 85.7 (80.8 to 90.7) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 4 | 86.3 (81.9 to 90.7) | 90.9 (87.3 to 94.5) | 90.2 (86.5 to 94.0) |
| Week 8 | 91.4 (87.8 to 95.0) | 93.3 (90.2 to 96.5) | 93.1 (89.9 to 96.4) |
| Week 12 | 93.5 (90.4 to 96.6) | 96.2 (93.7 to 98.6) | 92.8 (89.4 to 96.1) |
| Week 16 | 91.5 (87.8 to 95.1) | 94.7 (91.9 to 97.6) | 94.5 (91.6 to 97.4) |
| Week 20 | 94.2 (91.2 to 97.2) | 92.5 (89.1 to 95.9) | 92.1 (88.6 to 95.6) |
| Week 24 | 94.0 (90.9 to 97.1) | 93.4 (90.2 to 96.6) | 89.0 (85.0 to 93.1) |
| Week 28 | 90.9 (87.0 to 94.8) | 94.2 (91.1 to 97.2) | 92.6 (89.1 to 96.1) |
| Week 32 | 92.3 (88.5 to 96.0) | 94.2 (91.0 to 97.3) | 91.4 (87.7 to 95.2) |
| Week 36 | 93.1 (89.5 to 96.7) | 93.7 (90.4 to 97.0) | 89.4 (85.2 to 93.6) |
| Week 40 | 91.0 (87.0 to 94.9) | 93.6 (90.3 to 97.0) | 92.5 (88.9 to 96.2) |
| Week 44 | 91.8 (88.0 to 95.6) | 93.4 (90.0 to 96.7) | 91.6 (87.8 to 95.4) |
| Week 48 | 95.5 (92.6 to 98.4) | 91.9 (88.2 to 95.6) | 93.1 (89.7 to 96.6) |
| Week 52 | 89.8 (85.6 to 94.0) | 89.5 (85.4 to 93.6) | 90.9 (87.0 to 94.9) |
| Week 56 | 91.7 (87.8 to 95.6) | 92.7 (89.2 to 96.3) | 90.9 (86.9 to 94.9) |
| Week 60 | 89.9 (85.7 to 94.1) | 93.5 (90.1 to 96.9) | 91.9 (88.2 to 95.7) |
| Week 64 | 92.0 (88.1 to 95.9) | 92.6 (89.1 to 96.1) | 92.4 (88.7 to 96.1) |
| Week 68 | 92.0 (88.1 to 95.8) | 93.4 (90.0 to 96.8) | 91.8 (88.0 to 95.6) |
| Week 72 | 88.7 (84.1 to 93.2) | 92.0 (88.4 to 95.6) | 89.3 (84.9 to 93.7) |
| Week 76 | 86.8 (81.8 to 91.7) | 90.8 (86.8 to 94.8) | 91.6 (87.8 to 95.5) |
| Week 80 | 89.5 (85.0 to 94.0) | 90.7 (86.7 to 94.7) | 90.1 (85.8 to 94.3) |
| Week 84 | 87.4 (82.6 to 92.3) | 92.2 (88.5 to 95.8) | 92.5 (88.9 to 96.1) |
| Week 88 | 85.6 (80.4 to 90.7) | 88.8 (84.5 to 93.2) | 89.2 (84.7 to 93.7) |
| Week 92 | 88.8 (84.2 to 93.4) | 90.5 (86.5 to 94.6) | 91.0 (86.9 to 95.1) |
| Week 96 | 90.1 (85.7 to 94.6) | 87.2 (82.6 to 91.7) | 90.3 (86.1 to 94.6) |
| Week 100 | 87.8 (83.1 to 92.6) | 86.1 (81.4 to 90.8) | 92.0 (88.1 to 95.9) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Avoiding a Loss of ≥15 Letters | 98.1 (96.5 to 99.7) | 98.6 (97.2 to 100.0) | 98.9 (97.6 to 100.0) |
| Avoiding a Loss of ≥10 Letters | 96.3 (94.1 to 98.5) | 98.2 (96.6 to 99.8) | 98.1 (96.5 to 99.7) |
| Avoiding a Loss of ≥5 Letters | 95.2 (92.7 to 97.7) | 96.7 (94.7 to 98.8) | 96.3 (94.1 to 98.5) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 4 | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) |
| Week 8 | 99.7 (99.0 to 100.0) | 100.0 (100.0 to 100.0) | 99.3 (98.4 to 100.0) |
| Week 12 | 99.3 (98.5 to 100.0) | 100.0 (100.0 to 100.0) | 99.7 (99.0 to 100.0) |
| Week 16 | 99.7 (99.0 to 100.0) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) |
| Week 20 | 99.3 (98.4 to 100.0) | 99.3 (98.4 to 100.0) | 99.6 (99.0 to 100.0) |
| Week 24 | 99.6 (98.9 to 100.0) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) |
| Week 28 | 99.3 (98.2 to 100.0) | 99.7 (99.0 to 100.0) | 99.6 (99.0 to 100.0) |
| Week 32 | 99.6 (98.8 to 100.0) | 100.0 (100.0 to 100.0) | 99.3 (98.3 to 100.0) |
| Week 36 | 99.2 (98.0 to 100.0) | 99.2 (98.2 to 100.0) | 99.6 (98.8 to 100.0) |
| Week 40 | 98.8 (97.5 to 100.0) | 99.3 (98.2 to 100.0) | 99.6 (98.8 to 100.0) |
| Week 44 | 98.8 (97.5 to 100.0) | 98.9 (97.7 to 100.0) | 100.0 (100.0 to 100.0) |
| Week 48 | 98.4 (96.9 to 100.0) | 98.1 (96.5 to 99.7) | 99.3 (98.3 to 100.0) |
| Week 52 | 97.2 (95.2 to 99.2) | 98.1 (96.5 to 99.7) | 98.4 (96.8 to 99.9) |
| Week 56 | 98.4 (96.9 to 99.9) | 98.5 (97.0 to 100.0) | 98.4 (96.9 to 99.9) |
| Week 60 | 98.1 (96.4 to 99.7) | 98.5 (97.0 to 99.9) | 99.2 (98.1 to 100.0) |
| Week 64 | 98.8 (97.4 to 100.0) | 97.7 (95.8 to 99.5) | 98.8 (97.5 to 100.0) |
| Week 68 | 99.1 (98.0 to 100.0) | 98.0 (96.3 to 99.7) | 98.8 (97.5 to 100.0) |
| Week 72 | 97.2 (95.1 to 99.2) | 98.8 (97.5 to 100.0) | 98.8 (97.5 to 100.0) |
| Week 76 | 96.6 (94.4 to 98.9) | 98.0 (96.3 to 99.7) | 98.0 (96.3 to 99.7) |
| Week 80 | 97.6 (95.7 to 99.5) | 96.9 (94.8 to 99.0) | 99.1 (98.0 to 100.0) |
| Week 84 | 97.1 (95.0 to 99.2) | 98.1 (96.5 to 99.7) | 99.1 (98.0 to 100.0) |
| Week 88 | 97.1 (95.0 to 99.2) | 97.2 (95.2 to 99.2) | 97.9 (96.1 to 99.7) |
| Week 92 | 97.1 (95.0 to 99.2) | 97.4 (95.5 to 99.3) | 98.3 (96.6 to 99.9) |
| Week 96 | 97.4 (95.3 to 99.4) | 96.6 (94.4 to 98.8) | 97.8 (95.9 to 99.7) |
| Week 100 | 96.3 (93.9 to 98.7) | 97.0 (94.9 to 99.0) | 98.4 (96.8 to 99.9) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 4 | 98.7 (97.5 to 99.9) | 100.0 (100.0 to 100.0) | 99.4 (98.5 to 100.0) |
| Week 8 | 98.4 (97.0 to 99.8) | 100.0 (100.0 to 100.0) | 99.0 (97.9 to 100.0) |
| Week 12 | 98.7 (97.4 to 100.0) | 100.0 (100.0 to 100.0) | 99.3 (98.4 to 100.0) |
| Week 16 | 99.3 (98.4 to 100.0) | 99.3 (98.4 to 100.0) | 99.7 (99.0 to 100.0) |
| Week 20 | 99.0 (97.8 to 100.0) | 98.6 (97.3 to 100.0) | 99.3 (98.4 to 100.0) |
| Week 24 | 98.6 (97.2 to 100.0) | 99.7 (99.0 to 100.0) | 99.3 (98.4 to 100.0) |
| Week 28 | 97.4 (95.6 to 99.3) | 99.0 (97.8 to 100.0) | 98.6 (97.2 to 100.0) |
| Week 32 | 99.2 (98.1 to 100.0) | 98.5 (97.0 to 99.9) | 98.5 (97.1 to 99.9) |
| Week 36 | 98.4 (96.9 to 99.9) | 98.9 (97.6 to 100.0) | 99.2 (98.2 to 100.0) |
| Week 40 | 97.7 (95.9 to 99.5) | 99.3 (98.2 to 100.0) | 98.5 (97.0 to 99.9) |
| Week 44 | 97.3 (95.4 to 99.3) | 98.2 (96.6 to 99.8) | 99.2 (98.2 to 100.0) |
| Week 48 | 98.1 (96.4 to 99.7) | 97.8 (96.0 to 99.5) | 98.5 (97.1 to 99.9) |
| Week 52 | 95.3 (92.8 to 97.9) | 97.0 (95.0 to 99.0) | 96.8 (94.6 to 99.0) |
| Week 56 | 97.2 (95.2 to 99.2) | 98.1 (96.5 to 99.7) | 96.5 (94.3 to 98.7) |
| Week 60 | 96.9 (94.8 to 99.0) | 97.3 (95.4 to 99.3) | 98.1 (96.4 to 99.7) |
| Week 64 | 98.0 (96.3 to 99.7) | 96.5 (94.2 to 98.7) | 98.1 (96.4 to 99.7) |
| Week 68 | 96.9 (94.7 to 99.0) | 97.6 (95.8 to 99.5) | 98.4 (96.9 to 100.0) |
| Week 72 | 96.0 (93.6 to 98.4) | 98.0 (96.4 to 99.7) | 97.6 (95.7 to 99.5) |
| Week 76 | 95.9 (93.4 to 98.4) | 95.6 (93.1 to 98.1) | 97.6 (95.7 to 99.5) |
| Week 80 | 96.3 (94.0 to 98.7) | 96.2 (93.8 to 98.5) | 97.6 (95.9 to 99.5) |
| Week 84 | 95.5 (93.0 to 98.1) | 97.0 (95.0 to 99.0) | 99.1 (98.0 to 100.0) |
| Week 88 | 95.0 (92.3 to 97.7) | 95.6 (93.1 to 98.1) | 96.7 (94.5 to 98.9) |
| Week 92 | 95.9 (93.3 to 98.4) | 96.5 (94.3 to 98.7) | 97.5 (95.5 to 99.5) |
| Week 96 | 96.9 (94.7 to 99.2) | 94.3 (91.5 to 97.1) | 96.6 (94.3 to 98.9) |
| Week 100 | 94.3 (91.5 to 97.2) | 94.6 (91.8 to 97.3) | 97.1 (95.1 to 99.2) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 4 | 97.7 (96.1 to 99.4) | 97.4 (95.6 to 99.1) | 96.4 (94.4 to 98.4) |
| Week 8 | 96.4 (94.4 to 98.5) | 98.7 (97.5 to 100.0) | 97.3 (95.5 to 99.1) |
| Week 12 | 98.0 (96.5 to 99.6) | 98.0 (96.4 to 99.6) | 98.4 (97.0 to 99.8) |
| Week 16 | 97.3 (95.5 to 99.1) | 98.6 (97.3 to 100.0) | 98.7 (97.4 to 100.0) |
| Week 20 | 96.9 (95.0 to 98.9) | 97.2 (95.4 to 99.1) | 97.3 (95.4 to 99.1) |
| Week 24 | 96.9 (94.9 to 98.9) | 96.9 (94.9 to 98.9) | 96.6 (94.6 to 98.7) |
| Week 28 | 96.4 (94.2 to 98.6) | 97.6 (95.8 to 99.3) | 96.1 (93.9 to 98.4) |
| Week 32 | 96.6 (94.4 to 98.8) | 97.4 (95.5 to 99.3) | 97.5 (95.6 to 99.3) |
| Week 36 | 96.2 (93.9 to 98.5) | 97.3 (95.4 to 99.3) | 97.7 (96.0 to 99.5) |
| Week 40 | 95.2 (92.6 to 97.7) | 95.8 (93.4 to 98.2) | 97.7 (95.9 to 99.5) |
| Week 44 | 95.2 (92.6 to 97.7) | 96.7 (94.6 to 98.8) | 95.8 (93.4 to 98.2) |
| Week 48 | 96.6 (94.4 to 98.8) | 96.7 (94.5 to 98.8) | 96.9 (94.9 to 99.0) |
| Week 52 | 94.2 (91.4 to 97.0) | 95.9 (93.5 to 98.3) | 94.9 (92.2 to 97.6) |
| Week 56 | 96.0 (93.7 to 98.4) | 96.2 (93.8 to 98.5) | 95.0 (92.4 to 97.6) |
| Week 60 | 94.0 (91.2 to 96.8) | 96.2 (93.8 to 98.5) | 97.0 (94.9 to 99.0) |
| Week 64 | 95.7 (93.2 to 98.2) | 96.1 (93.8 to 98.5) | 96.1 (93.8 to 98.4) |
| Week 68 | 94.8 (92.1 to 97.6) | 96.4 (94.1 to 98.7) | 96.1 (93.8 to 98.5) |
| Week 72 | 93.3 (90.3 to 96.4) | 95.3 (92.7 to 97.9) | 94.4 (91.5 to 97.2) |
| Week 76 | 92.6 (89.4 to 95.9) | 94.8 (92.0 to 97.5) | 95.2 (92.6 to 97.8) |
| Week 80 | 94.0 (91.0 to 96.9) | 93.4 (90.4 to 96.4) | 94.0 (91.1 to 96.9) |
| Week 84 | 92.8 (89.6 to 96.0) | 95.8 (93.4 to 98.2) | 97.2 (95.1 to 99.2) |
| Week 88 | 89.8 (86.0 to 93.5) | 92.6 (89.4 to 95.8) | 94.7 (91.9 to 97.5) |
| Week 92 | 93.8 (90.8 to 96.8) | 92.7 (89.5 to 95.8) | 96.7 (94.4 to 98.9) |
| Week 96 | 94.9 (92.0 to 97.7) | 92.3 (89.1 to 95.5) | 95.0 (92.3 to 97.8) |
| Week 100 | 91.1 (87.6 to 94.6) | 88.9 (85.1 to 92.6) | 96.4 (94.1 to 98.6) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Avoiding a Loss of ≥15 Letters | 97.9 (96.0 to 99.9) | 98.1 (96.3 to 99.9) | 99.0 (97.7 to 100.0) |
| Avoiding a Loss of ≥10 Letters | 96.5 (93.9 to 99.0) | 97.7 (95.7 to 99.7) | 98.6 (97.0 to 100.0) |
| Avoiding a Loss of ≥5 Letters | 95.0 (91.9 to 98.0) | 95.8 (93.1 to 98.5) | 96.2 (93.6 to 98.8) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 4 | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) |
| Week 8 | 99.6 (98.7 to 100.0) | 100.0 (100.0 to 100.0) | 99.6 (98.8 to 100.0) |
| Week 12 | 99.6 (98.7 to 100.0) | 100.0 (100.0 to 100.0) | 99.6 (98.7 to 100.0) |
| Week 16 | 99.6 (98.7 to 100.0) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) |
| Week 20 | 99.1 (97.9 to 100.0) | 99.1 (97.9 to 100.0) | 100.0 (100.0 to 100.0) |
| Week 24 | 99.5 (98.6 to 100.0) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) |
| Week 28 | 99.0 (97.6 to 100.0) | 99.6 (98.7 to 100.0) | 99.5 (98.6 to 100.0) |
| Week 32 | 99.5 (98.4 to 100.0) | 100.0 (100.0 to 100.0) | 99.0 (97.7 to 100.0) |
| Week 36 | 98.9 (97.3 to 100.0) | 99.0 (97.6 to 100.0) | 99.5 (98.4 to 100.0) |
| Week 40 | 98.4 (96.6 to 100.0) | 99.0 (97.7 to 100.0) | 99.5 (98.4 to 100.0) |
| Week 44 | 98.9 (97.5 to 100.0) | 98.6 (97.0 to 100.0) | 100.0 (100.0 to 100.0) |
| Week 48 | 98.4 (96.6 to 100.0) | 97.6 (95.5 to 99.7) | 99.0 (97.7 to 100.0) |
| Week 52 | 96.8 (94.3 to 99.3) | 97.6 (95.5 to 99.7) | 98.4 (96.6 to 100.0) |
| Week 56 | 98.4 (96.7 to 100.0) | 98.1 (96.2 to 99.9) | 98.5 (96.7 to 100.0) |
| Week 60 | 97.4 (95.2 to 99.6) | 98.0 (96.1 to 99.9) | 99.0 (97.5 to 100.0) |
| Week 64 | 98.4 (96.5 to 100.0) | 97.0 (94.6 to 99.4) | 98.4 (96.7 to 100.0) |
| Week 68 | 98.9 (97.3 to 100.0) | 97.4 (95.2 to 99.6) | 98.4 (96.7 to 100.0) |
| Week 72 | 96.2 (93.4 to 98.9) | 98.5 (96.8 to 100.0) | 98.4 (96.6 to 100.0) |
| Week 76 | 95.5 (92.4 to 98.5) | 97.4 (95.2 to 99.6) | 97.9 (95.9 to 99.9) |
| Week 80 | 96.7 (94.1 to 99.3) | 96.6 (94.1 to 99.1) | 98.8 (97.3 to 100.0) |
| Week 84 | 96.1 (93.3 to 98.9) | 98.0 (96.1 to 99.9) | 99.5 (98.4 to 100.0) |
| Week 88 | 96.1 (93.2 to 98.9) | 97.5 (95.3 to 99.6) | 97.7 (95.5 to 99.9) |
| Week 92 | 96.1 (93.2 to 98.9) | 97.0 (94.7 to 99.3) | 98.3 (96.4 to 100.0) |
| Week 96 | 97.1 (94.6 to 99.6) | 96.1 (93.4 to 98.7) | 98.9 (97.3 to 100.0) |
| Week 100 | 96.1 (93.3 to 98.9) | 97.1 (94.8 to 99.4) | 98.4 (96.6 to 100.0) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 4 | 99.6 (98.7 to 100.0) | 100.0 (100.0 to 100.0) | 99.2 (98.0 to 100.0) |
| Week 8 | 98.3 (96.6 to 100.0) | 100.0 (100.0 to 100.0) | 99.6 (98.8 to 100.0) |
| Week 12 | 99.1 (97.9 to 100.0) | 100.0 (100.0 to 100.0) | 99.6 (98.7 to 100.0) |
| Week 16 | 99.1 (97.9 to 100.0) | 99.1 (97.9 to 100.0) | 100.0 (100.0 to 100.0) |
| Week 20 | 99.1 (97.9 to 100.0) | 98.3 (96.6 to 99.9) | 100.0 (100.0 to 100.0) |
| Week 24 | 99.1 (97.8 to 100.0) | 99.6 (98.7 to 100.0) | 99.1 (97.9 to 100.0) |
| Week 28 | 98.0 (96.1 to 99.9) | 98.7 (97.2 to 100.0) | 98.6 (97.1 to 100.0) |
| Week 32 | 99.5 (98.4 to 100.0) | 98.0 (96.1 to 99.9) | 98.1 (96.2 to 99.9) |
| Week 36 | 97.9 (95.8 to 99.9) | 98.5 (96.8 to 100.0) | 99.0 (97.6 to 100.0) |
| Week 40 | 96.9 (94.5 to 99.3) | 99.0 (97.7 to 100.0) | 97.9 (95.9 to 99.9) |
| Week 44 | 97.4 (95.2 to 99.6) | 97.6 (95.6 to 99.7) | 99.0 (97.6 to 100.0) |
| Week 48 | 97.9 (95.9 to 99.9) | 97.1 (94.9 to 99.4) | 98.5 (96.9 to 100.0) |
| Week 52 | 95.3 (92.3 to 98.3) | 96.2 (93.6 to 98.8) | 96.8 (94.4 to 99.3) |
| Week 56 | 97.4 (95.2 to 99.6) | 97.6 (95.5 to 99.7) | 96.4 (93.9 to 99.0) |
| Week 60 | 96.4 (93.8 to 99.0) | 96.5 (93.9 to 99.0) | 97.9 (95.9 to 99.9) |
| Week 64 | 97.3 (95.0 to 99.6) | 96.5 (94.0 to 99.1) | 97.4 (95.2 to 99.6) |
| Week 68 | 96.8 (94.3 to 99.3) | 96.9 (94.6 to 99.3) | 97.9 (95.9 to 99.9) |
| Week 72 | 95.1 (92.0 to 98.2) | 98.0 (96.1 to 99.9) | 97.3 (95.0 to 99.6) |
| Week 76 | 94.9 (91.7 to 98.2) | 94.3 (91.1 to 97.6) | 97.4 (95.1 to 99.6) |
| Week 80 | 95.0 (91.8 to 98.2) | 95.6 (92.8 to 98.4) | 97.3 (94.9 to 99.6) |
| Week 84 | 94.0 (90.5 to 97.4) | 97.1 (94.7 to 99.4) | 99.5 (98.4 to 100.0) |
| Week 88 | 93.9 (90.4 to 97.4) | 95.4 (92.5 to 98.3) | 96.1 (93.3 to 98.9) |
| Week 92 | 95.0 (91.8 to 98.2) | 96.5 (94.0 to 99.0) | 97.2 (94.9 to 99.6) |
| Week 96 | 96.5 (93.7 to 99.3) | 93.6 (90.2 to 97.0) | 97.2 (94.8 to 99.6) |
| Week 100 | 93.9 (90.4 to 97.4) | 94.6 (91.5 to 97.7) | 97.3 (94.9 to 99.6) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 4 | 98.7 (97.3 to 100.0) | 97.5 (95.5 to 99.5) | 97.0 (94.9 to 99.2) |
| Week 8 | 96.5 (94.2 to 98.8) | 99.2 (98.1 to 100.0) | 98.3 (96.6 to 99.9) |
| Week 12 | 98.3 (96.6 to 99.9) | 98.7 (97.3 to 100.0) | 98.7 (97.3 to 100.0) |
| Week 16 | 97.8 (95.8 to 99.7) | 98.3 (96.6 to 99.9) | 98.7 (97.3 to 100.0) |
| Week 20 | 97.3 (95.2 to 99.4) | 96.5 (94.2 to 98.9) | 97.8 (95.9 to 99.7) |
| Week 24 | 97.7 (95.7 to 99.7) | 96.1 (93.5 to 98.6) | 96.5 (94.1 to 98.9) |
| Week 28 | 96.6 (94.1 to 99.0) | 97.3 (95.2 to 99.4) | 96.8 (94.5 to 99.1) |
| Week 32 | 97.4 (95.1 to 99.6) | 96.6 (94.1 to 99.1) | 97.6 (95.5 to 99.7) |
| Week 36 | 96.3 (93.6 to 99.0) | 97.6 (95.4 to 99.7) | 98.1 (96.2 to 99.9) |
| Week 40 | 94.5 (91.3 to 97.6) | 95.6 (92.7 to 98.4) | 96.9 (94.5 to 99.3) |
| Week 44 | 95.9 (93.2 to 98.7) | 95.8 (93.1 to 98.5) | 96.5 (93.9 to 99.0) |
| Week 48 | 96.4 (93.8 to 99.0) | 95.7 (93.0 to 98.5) | 97.5 (95.4 to 99.7) |
| Week 52 | 94.3 (91.1 to 97.6) | 94.8 (91.7 to 97.8) | 94.4 (91.2 to 97.6) |
| Week 56 | 95.8 (93.0 to 98.6) | 95.6 (92.9 to 98.4) | 94.4 (91.3 to 97.6) |
| Week 60 | 94.4 (91.2 to 97.6) | 96.0 (93.3 to 98.7) | 96.9 (94.6 to 99.3) |
| Week 64 | 95.2 (92.2 to 98.3) | 96.0 (93.3 to 98.7) | 95.8 (93.0 to 98.6) |
| Week 68 | 94.6 (91.4 to 97.9) | 95.9 (93.2 to 98.7) | 96.4 (93.8 to 99.0) |
| Week 72 | 92.6 (88.8 to 96.3) | 95.9 (93.2 to 98.7) | 94.7 (91.4 to 97.9) |
| Week 76 | 91.1 (86.9 to 95.3) | 93.8 (90.5 to 97.2) | 94.7 (91.5 to 97.9) |
| Week 80 | 92.8 (89.0 to 96.6) | 92.6 (89.1 to 96.2) | 94.2 (90.9 to 97.5) |
| Week 84 | 91.9 (87.9 to 95.8) | 96.1 (93.4 to 98.7) | 96.9 (94.4 to 99.3) |
| Week 88 | 88.3 (83.6 to 93.0) | 91.9 (88.1 to 95.7) | 93.5 (89.9 to 97.0) |
| Week 92 | 92.7 (88.9 to 96.5) | 92.5 (88.9 to 96.2) | 96.7 (94.1 to 99.3) |
| Week 96 | 94.8 (91.4 to 98.1) | 91.5 (87.7 to 95.4) | 95.2 (92.1 to 98.3) |
| Week 100 | 90.6 (86.4 to 94.9) | 88.1 (83.7 to 92.5) | 96.8 (94.2 to 99.3) |
BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| ITT Population | 32.1 (26.6 to 37.6) | 39.1 (33.5 to 44.7) | 37.0 (31.5 to 42.5) |
| Treatment-Naive Population | 31.5 (25.1 to 38.0) | 39.2 (32.8 to 45.5) | 40.2 (33.7 to 46.6) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 4 | 8.7 (5.6 to 11.8) | 14.6 (10.8 to 18.4) | 13.3 (9.6 to 17.0) |
| Week 8 | 15.3 (11.3 to 19.3) | 20.1 (15.9 to 24.4) | 19.9 (15.6 to 24.3) |
| Week 12 | 17.9 (13.6 to 22.1) | 25.7 (21.1 to 30.4) | 25.3 (20.6 to 30.0) |
| Week 16 | 24.1 (19.2 to 28.9) | 29.1 (24.2 to 34.0) | 25.2 (20.5 to 30.0) |
| Week 20 | 30.1 (24.9 to 35.2) | 30.8 (25.6 to 35.9) | 27.7 (22.8 to 32.6) |
| Week 24 | 31.3 (26.0 to 36.5) | 37.8 (32.5 to 43.2) | 30.9 (25.7 to 36.0) |
| Week 28 | 28.3 (23.1 to 33.5) | 32.6 (27.4 to 37.8) | 35.0 (29.7 to 40.4) |
| Week 32 | 33.7 (28.0 to 39.3) | 38.8 (33.2 to 44.4) | 31.0 (25.8 to 36.2) |
| Week 36 | 29.6 (24.1 to 35.0) | 42.4 (36.8 to 48.1) | 35.6 (30.0 to 41.1) |
| Week 40 | 32.9 (27.4 to 38.5) | 40.4 (34.7 to 46.2) | 33.8 (28.2 to 39.4) |
| Week 44 | 32.1 (26.5 to 37.7) | 39.7 (34.1 to 45.3) | 39.9 (34.2 to 45.7) |
| Week 48 | 35.7 (30.0 to 41.5) | 41.8 (36.1 to 47.6) | 41.7 (36.0 to 47.4) |
| Week 52 | 35.7 (29.9 to 41.4) | 40.2 (34.5 to 45.8) | 41.7 (35.8 to 47.6) |
| Week 56 | 43.1 (37.1 to 49.1) | 42.6 (36.7 to 48.4) | 35.7 (30.1 to 41.4) |
| Week 60 | 39.5 (33.7 to 45.3) | 45.0 (39.1 to 51.0) | 40.6 (34.8 to 46.3) |
| Week 64 | 42.1 (36.1 to 48.1) | 44.0 (38.2 to 49.8) | 37.9 (32.1 to 43.7) |
| Week 68 | 42.2 (36.2 to 48.2) | 45.6 (39.7 to 51.6) | 40.3 (34.5 to 46.2) |
| Week 72 | 39.8 (33.9 to 45.8) | 40.5 (34.8 to 46.2) | 37.7 (31.8 to 43.6) |
| Week 76 | 42.2 (36.1 to 48.4) | 47.7 (41.8 to 53.5) | 42.9 (36.8 to 49.0) |
| Week 80 | 42.9 (36.8 to 49.0) | 44.8 (39.0 to 50.5) | 41.9 (35.9 to 47.8) |
| Week 84 | 42.4 (36.3 to 48.5) | 43.0 (37.2 to 48.7) | 42.9 (36.9 to 48.9) |
| Week 88 | 41.2 (35.1 to 47.3) | 41.7 (36.1 to 47.4) | 40.0 (34.1 to 46.0) |
| Week 92 | 42.5 (36.4 to 48.5) | 43.6 (37.8 to 49.4) | 42.7 (36.7 to 48.7) |
| Week 96 | 44.9 (38.7 to 51.1) | 42.4 (36.6 to 48.1) | 42.7 (36.6 to 48.7) |
| Week 100 | 43.5 (37.5 to 49.6) | 41.8 (36.1 to 47.5) | 44.7 (38.6 to 50.8) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 4 | 9.8 (6.0 to 13.5) | 17.0 (12.4 to 21.6) | 15.2 (10.7 to 19.8) |
| Week 8 | 16.0 (11.3 to 20.7) | 20.9 (16.1 to 25.7) | 22.2 (16.9 to 27.4) |
| Week 12 | 19.2 (14.1 to 24.2) | 25.6 (20.3 to 30.9) | 28.5 (22.9 to 34.1) |
| Week 16 | 24.9 (19.2 to 30.5) | 29.5 (23.8 to 35.2) | 27.9 (22.2 to 33.6) |
| Week 20 | 31.0 (25.0 to 37.0) | 30.4 (24.6 to 36.1) | 30.6 (24.8 to 36.4) |
| Week 24 | 32.5 (26.3 to 38.7) | 38.2 (32.1 to 44.3) | 33.3 (27.3 to 39.4) |
| Week 28 | 26.9 (20.9 to 32.9) | 32.0 (26.2 to 37.8) | 38.5 (32.2 to 44.8) |
| Week 32 | 33.3 (26.7 to 39.9) | 40.5 (34.0 to 46.9) | 35.4 (29.0 to 41.7) |
| Week 36 | 29.5 (23.1 to 36.0) | 44.8 (38.3 to 51.3) | 38.4 (31.9 to 44.8) |
| Week 40 | 31.5 (25.1 to 37.9) | 41.1 (34.5 to 47.7) | 37.1 (30.4 to 43.7) |
| Week 44 | 31.1 (24.7 to 37.6) | 42.9 (36.4 to 49.5) | 42.7 (36.0 to 49.4) |
| Week 48 | 37.5 (30.7 to 44.3) | 41.9 (35.3 to 48.5) | 44.9 (38.2 to 51.6) |
| Week 52 | 35.5 (28.9 to 42.2) | 39.2 (32.8 to 45.6) | 43.8 (36.9 to 50.6) |
| Week 56 | 43.3 (36.3 to 50.3) | 43.1 (36.5 to 49.7) | 38.9 (32.2 to 45.5) |
| Week 60 | 39.4 (32.6 to 46.2) | 46.7 (39.9 to 53.5) | 43.6 (36.8 to 50.4) |
| Week 64 | 43.0 (36.0 to 50.0) | 46.4 (39.8 to 53.1) | 38.7 (32.0 to 45.3) |
| Week 68 | 43.7 (36.6 to 50.7) | 47.9 (41.1 to 54.7) | 42.2 (35.4 to 49.0) |
| Week 72 | 40.7 (33.7 to 47.8) | 42.1 (35.5 to 48.7) | 39.3 (32.5 to 46.2) |
| Week 76 | 44.6 (37.3 to 51.8) | 49.9 (43.3 to 56.6) | 43.8 (36.8 to 50.8) |
| Week 80 | 44.6 (37.3 to 51.8) | 46.6 (40.1 to 53.2) | 46.1 (39.1 to 53.1) |
| Week 84 | 42.7 (35.6 to 49.9) | 45.2 (38.6 to 51.7) | 45.7 (38.7 to 52.7) |
| Week 88 | 41.3 (34.2 to 48.5) | 42.7 (36.3 to 49.2) | 42.5 (35.5 to 49.6) |
| Week 92 | 43.4 (36.3 to 50.6) | 45.5 (38.9 to 52.1) | 43.9 (36.9 to 50.8) |
| Week 96 | 46.7 (39.3 to 54.1) | 43.6 (37.2 to 50.1) | 44.7 (37.7 to 51.8) |
| Week 100 | 44.1 (37.0 to 51.3) | 44.4 (37.9 to 50.9) | 45.8 (38.8 to 52.9) |
BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥69 vs. \<69 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| ITT Population | 71.6 (66.5 to 76.6) | 77.1 (72.4 to 81.8) | 74.8 (69.9 to 79.6) |
| Treatment-Naive Population | 72.7 (66.9 to 78.5) | 75.7 (70.3 to 81.1) | 77.4 (72.2 to 82.7) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥69 vs. \<69 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 4 | 53.3 (48.4 to 58.1) | 60.0 (55.1 to 64.8) | 57.5 (52.6 to 62.4) |
| Week 8 | 60.0 (55.1 to 64.9) | 65.5 (60.8 to 70.1) | 66.1 (61.4 to 70.8) |
| Week 12 | 64.4 (59.4 to 69.3) | 69.3 (64.6 to 74.0) | 68.8 (64.1 to 73.6) |
| Week 16 | 66.1 (61.1 to 71.2) | 70.6 (65.8 to 75.3) | 74.7 (70.1 to 79.2) |
| Week 20 | 70.3 (65.4 to 75.3) | 69.7 (64.9 to 74.6) | 70.3 (65.5 to 75.1) |
| Week 24 | 71.0 (66.1 to 76.0) | 76.0 (71.4 to 80.6) | 71.0 (66.3 to 75.8) |
| Week 28 | 71.5 (66.5 to 76.4) | 74.5 (69.9 to 79.1) | 75.1 (70.4 to 79.8) |
| Week 32 | 71.4 (66.3 to 76.5) | 74.1 (69.2 to 79.0) | 74.9 (70.1 to 79.7) |
| Week 36 | 71.8 (66.8 to 76.9) | 79.4 (74.7 to 84.1) | 73.2 (68.1 to 78.2) |
| Week 40 | 69.3 (64.2 to 74.4) | 75.1 (70.2 to 80.1) | 73.6 (68.5 to 78.7) |
| Week 44 | 70.6 (65.4 to 75.7) | 77.7 (72.9 to 82.5) | 73.4 (68.3 to 78.4) |
| Week 48 | 73.4 (68.4 to 78.4) | 78.3 (73.6 to 83.0) | 72.7 (67.6 to 77.8) |
| Week 52 | 69.3 (63.9 to 74.6) | 76.6 (71.7 to 81.4) | 75.2 (70.2 to 80.2) |
| Week 56 | 74.9 (69.9 to 79.9) | 79.5 (74.8 to 84.2) | 72.2 (67.0 to 77.4) |
| Week 60 | 71.8 (66.6 to 76.9) | 76.6 (71.6 to 81.5) | 75.9 (70.9 to 80.9) |
| Week 64 | 74.9 (69.8 to 79.9) | 76.2 (71.4 to 81.0) | 71.4 (66.3 to 76.5) |
| Week 68 | 74.4 (69.2 to 79.7) | 78.0 (73.2 to 82.8) | 73.9 (68.9 to 78.9) |
| Week 72 | 73.9 (68.6 to 79.1) | 76.8 (72.0 to 81.7) | 71.0 (65.8 to 76.1) |
| Week 76 | 72.6 (67.2 to 78.0) | 77.0 (72.0 to 82.0) | 76.0 (71.1 to 81.0) |
| Week 80 | 74.6 (69.3 to 79.9) | 77.5 (72.5 to 82.4) | 73.8 (68.7 to 78.9) |
| Week 84 | 73.7 (68.4 to 79.1) | 77.2 (72.3 to 82.1) | 77.3 (72.5 to 82.2) |
| Week 88 | 72.2 (66.7 to 77.7) | 76.2 (71.2 to 81.3) | 73.3 (68.0 to 78.5) |
| Week 92 | 75.3 (70.0 to 80.6) | 78.4 (73.4 to 83.3) | 77.4 (72.6 to 82.2) |
| Week 96 | 75.9 (70.6 to 81.2) | 74.3 (69.0 to 79.5) | 73.4 (68.3 to 78.5) |
| Week 100 | 75.9 (70.7 to 81.1) | 70.3 (64.9 to 75.7) | 75.7 (70.8 to 80.7) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥69 vs. \<69 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 4 | 55.7 (50.1 to 61.2) | 60.4 (55.0 to 65.8) | 60.4 (54.9 to 65.9) |
| Week 8 | 62.0 (56.5 to 67.6) | 66.5 (61.3 to 71.6) | 69.6 (64.3 to 74.8) |
| Week 12 | 66.2 (60.5 to 71.8) | 69.3 (64.1 to 74.5) | 70.6 (65.3 to 75.9) |
| Week 16 | 68.5 (62.8 to 74.2) | 68.5 (63.1 to 74.0) | 75.8 (70.8 to 80.9) |
| Week 20 | 72.7 (67.1 to 78.2) | 67.8 (62.2 to 73.4) | 72.0 (66.7 to 77.3) |
| Week 24 | 73.7 (68.2 to 79.3) | 74.5 (69.2 to 79.8) | 72.6 (67.3 to 77.9) |
| Week 28 | 73.7 (68.2 to 79.3) | 73.1 (67.8 to 78.4) | 77.0 (71.8 to 82.2) |
| Week 32 | 71.8 (65.8 to 77.7) | 72.4 (66.7 to 78.1) | 75.8 (70.4 to 81.2) |
| Week 36 | 74.7 (68.9 to 80.5) | 79.4 (74.0 to 84.7) | 73.4 (67.6 to 79.1) |
| Week 40 | 70.6 (64.7 to 76.6) | 74.6 (68.9 to 80.3) | 75.8 (70.2 to 81.4) |
| Week 44 | 71.1 (65.2 to 77.1) | 76.9 (71.3 to 82.4) | 76.4 (70.8 to 82.0) |
| Week 48 | 74.3 (68.6 to 80.0) | 75.7 (70.2 to 81.2) | 75.3 (69.8 to 80.9) |
| Week 52 | 71.7 (65.6 to 77.7) | 74.4 (68.7 to 80.1) | 77.5 (71.9 to 83.0) |
| Week 56 | 76.9 (71.3 to 82.5) | 77.9 (72.4 to 83.4) | 74.0 (68.2 to 79.7) |
| Week 60 | 73.4 (67.5 to 79.3) | 75.2 (69.4 to 81.0) | 78.3 (72.8 to 83.8) |
| Week 64 | 77.0 (71.2 to 82.7) | 75.5 (69.9 to 81.0) | 74.4 (68.9 to 80.0) |
| Week 68 | 77.6 (71.7 to 83.5) | 77.9 (72.4 to 83.3) | 75.5 (69.9 to 81.0) |
| Week 72 | 76.7 (70.7 to 82.6) | 75.9 (70.3 to 81.4) | 74.5 (68.9 to 80.1) |
| Week 76 | 72.7 (66.3 to 79.1) | 75.8 (70.1 to 81.5) | 78.0 (72.6 to 83.3) |
| Week 80 | 76.4 (70.2 to 82.6) | 76.8 (71.2 to 82.5) | 76.5 (70.9 to 82.1) |
| Week 84 | 75.7 (69.5 to 81.9) | 77.8 (72.3 to 83.3) | 77.8 (72.4 to 83.2) |
| Week 88 | 71.8 (65.2 to 78.3) | 75.7 (69.9 to 81.5) | 76.0 (70.1 to 81.9) |
| Week 92 | 75.9 (69.7 to 82.1) | 77.7 (71.9 to 83.4) | 79.9 (74.7 to 85.2) |
| Week 96 | 77.3 (71.1 to 83.4) | 73.5 (67.4 to 79.5) | 75.5 (69.9 to 81.2) |
| Week 100 | 77.6 (71.6 to 83.6) | 70.8 (64.6 to 76.9) | 77.0 (71.4 to 82.5) |
BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| ITT Population | 2.3 (0.5 to 4.1) | 1.9 (0.3 to 3.5) | 1.7 (0.3 to 3.2) |
| Treatment-Naive Population | 2.6 (0.4 to 4.8) | 1.9 (0.1 to 3.7) | 1.8 (0.1 to 3.5) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement invisual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 4 | 1.9 (0.4 to 3.4) | 2.6 (0.9 to 4.3) | 1.6 (0.2 to 3.0) |
| Week 8 | 2.0 (0.4 to 3.5) | 3.0 (1.1 to 4.8) | 2.0 (0.4 to 3.5) |
| Week 12 | 1.6 (0.2 to 3.0) | 2.0 (0.5 to 3.5) | 1.6 (0.2 to 3.0) |
| Week 16 | 0.7 (0.0 to 1.6) | 2.1 (0.5 to 3.7) | 1.6 (0.2 to 3.0) |
| Week 20 | 1.3 (0.0 to 2.7) | 1.7 (0.3 to 3.2) | 1.7 (0.2 to 3.1) |
| Week 24 | 0.7 (0.0 to 1.6) | 1.7 (0.3 to 3.2) | 1.7 (0.3 to 3.1) |
| Week 28 | 1.4 (0.1 to 2.8) | 1.4 (0.1 to 2.8) | 1.4 (0.1 to 2.7) |
| Week 32 | 1.1 (0.0 to 2.4) | 1.2 (0.0 to 2.4) | 1.8 (0.2 to 3.3) |
| Week 36 | 1.6 (0.1 to 3.1) | 1.6 (0.1 to 3.1) | 1.5 (0.1 to 3.0) |
| Week 40 | 1.5 (0.1 to 3.0) | 2.3 (0.5 to 4.1) | 1.5 (0.1 to 2.9) |
| Week 44 | 3.1 (1.0 to 5.2) | 1.9 (0.3 to 3.6) | 1.4 (0.1 to 2.8) |
| Week 48 | 1.6 (0.1 to 3.1) | 2.3 (0.5 to 4.1) | 1.8 (0.3 to 3.3) |
| Week 52 | 2.0 (0.3 to 3.8) | 1.5 (0.1 to 3.0) | 1.5 (0.1 to 2.9) |
| Week 56 | 1.5 (0.0 to 3.0) | 1.6 (0.1 to 3.1) | 1.9 (0.3 to 3.5) |
| Week 60 | 1.9 (0.3 to 3.5) | 1.2 (0.0 to 2.5) | 1.4 (0.1 to 2.8) |
| Week 64 | 1.2 (0.0 to 2.6) | 2.5 (0.6 to 4.3) | 1.8 (0.2 to 3.3) |
| Week 68 | 1.3 (0.0 to 2.7) | 2.4 (0.6 to 4.3) | 1.8 (0.3 to 3.4) |
| Week 72 | 1.3 (0.0 to 2.7) | 1.6 (0.1 to 3.1) | 1.5 (0.1 to 2.9) |
| Week 76 | 0.9 (0.0 to 2.1) | 1.6 (0.1 to 3.2) | 3.4 (1.3 to 5.6) |
| Week 80 | 0.9 (0.0 to 2.1) | 2.0 (0.3 to 3.8) | 3.0 (1.0 to 5.0) |
| Week 84 | 0.9 (0.0 to 2.1) | 1.6 (0.1 to 3.2) | 1.0 (0.0 to 2.2) |
| Week 88 | 1.3 (0.0 to 2.7) | 1.7 (0.1 to 3.2) | 2.0 (0.3 to 3.8) |
| Week 92 | 2.2 (0.3 to 4.0) | 2.1 (0.4 to 3.9) | 2.8 (0.8 to 4.8) |
| Week 96 | 1.7 (0.1 to 3.4) | 2.1 (0.3 to 3.8) | 0.9 (0.0 to 2.1) |
| Week 100 | 2.5 (0.5 to 4.5) | 2.1 (0.3 to 3.8) | 1.2 (0.0 to 2.6) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 4 | 1.7 (0.1 to 3.3) | 2.9 (0.8 to 4.9) | 1.3 (0.0 to 2.7) |
| Week 8 | 2.2 (0.3 to 4.0) | 3.3 (1.1 to 5.5) | 2.1 (0.3 to 3.9) |
| Week 12 | 1.3 (0.0 to 2.7) | 2.1 (0.3 to 3.9) | 1.7 (0.1 to 3.3) |
| Week 16 | 0.5 (0.0 to 1.3) | 2.2 (0.3 to 4.0) | 1.7 (0.1 to 3.3) |
| Week 20 | 1.3 (0.0 to 2.8) | 1.7 (0.1 to 3.4) | 1.7 (0.1 to 3.4) |
| Week 24 | 0.5 (0.0 to 1.4) | 1.7 (0.1 to 3.4) | 1.3 (0.0 to 2.7) |
| Week 28 | 1.0 (0.0 to 2.4) | 1.3 (0.0 to 2.9) | 1.3 (0.0 to 2.8) |
| Week 32 | 1.1 (0.0 to 2.5) | 1.0 (0.0 to 2.3) | 1.9 (0.1 to 3.7) |
| Week 36 | 1.7 (0.0 to 3.5) | 1.0 (0.0 to 2.4) | 1.5 (0.0 to 3.1) |
| Week 40 | 1.6 (0.0 to 3.3) | 2.0 (0.1 to 3.9) | 1.4 (0.0 to 3.0) |
| Week 44 | 2.7 (0.4 to 4.9) | 2.0 (0.1 to 3.8) | 1.4 (0.0 to 2.9) |
| Week 48 | 1.6 (0.0 to 3.4) | 2.4 (0.3 to 4.5) | 1.9 (0.1 to 3.7) |
| Week 52 | 2.7 (0.4 to 5.0) | 1.9 (0.1 to 3.8) | 1.4 (0.0 to 3.0) |
| Week 56 | 1.0 (0.0 to 2.5) | 1.5 (0.0 to 3.1) | 2.0 (0.1 to 3.9) |
| Week 60 | 2.1 (0.1 to 4.1) | 1.0 (0.0 to 2.4) | 1.9 (0.1 to 3.8) |
| Week 64 | 1.6 (0.0 to 3.5) | 2.0 (0.1 to 4.0) | 1.9 (0.1 to 3.7) |
| Week 68 | 1.1 (0.0 to 2.7) | 1.6 (0.0 to 3.3) | 1.9 (0.1 to 3.7) |
| Week 72 | 1.7 (0.0 to 3.6) | 1.0 (0.0 to 2.4) | 1.4 (0.0 to 3.0) |
| Week 76 | 1.2 (0.0 to 2.8) | 1.5 (0.0 to 3.2) | 3.5 (1.0 to 6.0) |
| Week 80 | 1.2 (0.0 to 2.8) | 2.0 (0.1 to 4.0) | 3.5 (1.0 to 6.0) |
| Week 84 | 1.2 (0.0 to 2.8) | 1.0 (0.0 to 2.4) | 1.4 (0.0 to 2.9) |
| Week 88 | 1.7 (0.0 to 3.7) | 1.0 (0.0 to 2.4) | 2.1 (0.1 to 4.2) |
| Week 92 | 2.4 (0.1 to 4.6) | 1.5 (0.0 to 3.3) | 2.6 (0.3 to 4.9) |
| Week 96 | 1.3 (0.0 to 3.0) | 2.1 (0.1 to 4.0) | 0.6 (0.0 to 1.7) |
| Week 100 | 2.3 (0.1 to 4.5) | 2.1 (0.1 to 4.1) | 1.1 (0.0 to 2.6) |
The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 16 | 36.7 (31.2 to 42.3) | 35.0 (29.6 to 40.5) | 28.9 (23.9 to 34.0) |
| Week 52 | 46.2 (40.0 to 52.3) | 42.3 (36.4 to 48.3) | 35.4 (29.6 to 41.2) |
| Week 96 | 51.4 (44.8 to 57.9) | 42.8 (36.6 to 49.0) | 42.2 (35.9 to 48.5) |
The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 16 | 39.3 (32.7 to 45.8) | 39.5 (33.2 to 45.9) | 33.3 (27.1 to 39.4) |
| Week 52 | 49.5 (42.3 to 56.8) | 47.4 (40.5 to 54.4) | 42.3 (35.3 to 49.3) |
| Week 96 | 52.3 (44.6 to 60.1) | 47.0 (39.7 to 54.2) | 49.1 (41.7 to 56.6) |
The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 16 | 12.7 (8.8 to 16.5) | 12.8 (9.0 to 16.6) | 10.3 (6.8 to 13.8) |
| Week 52 | 17.0 (12.3 to 21.6) | 15.3 (10.9 to 19.8) | 14.2 (10.0 to 18.5) |
| Week 96 | 22.4 (16.9 to 27.8) | 14.6 (10.0 to 19.1) | 20.9 (15.8 to 26.0) |
The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 16 | 14.4 (9.7 to 19.1) | 15.1 (10.4 to 19.8) | 10.4 (6.4 to 14.4) |
| Week 52 | 19.5 (13.7 to 25.2) | 17.4 (12.1 to 22.8) | 16.4 (11.2 to 21.6) |
| Week 96 | 23.9 (17.3 to 30.5) | 17.1 (11.5 to 22.6) | 25.3 (18.9 to 31.6) |
The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 16 | 3.6 (1.4 to 5.8) | 3.5 (1.4 to 5.6) | 3.9 (1.7 to 6.2) |
| Week 52 | 5.8 (2.9 to 8.7) | 4.9 (2.2 to 7.7) | 4.5 (1.9 to 7.0) |
| Week 96 | 5.9 (2.8 to 9.0) | 5.8 (2.8 to 8.8) | 6.0 (3.0 to 9.0) |
The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 16 | 3.9 (1.3 to 6.4) | 3.5 (1.1 to 5.9) | 3.6 (1.2 to 6.1) |
| Week 52 | 6.2 (2.7 to 9.7) | 5.1 (2.0 to 8.3) | 4.2 (1.4 to 7.0) |
| Week 96 | 7.0 (3.0 to 11.0) | 6.8 (3.1 to 10.5) | 6.3 (2.8 to 9.8) |
The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy (PDR). PDR was defined as an ETDRS DRSS score of ≥61 on the 7-field/4-wide field color fundus photographs assessment by a central reading center. The weighted percentages of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% CI is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| ITT Population | 0.9 (0.0 to 2.2) | 0.9 (0.0 to 2.2) | 0.5 (0.0 to 1.4) |
| Treatment-Naive Population | 0.0 (0.0 to 0.0) | 1.2 (0.0 to 2.8) | 0.6 (0.0 to 1.9) |
The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced PDR. High-risk PDR was defined as an ETDRS DRSS score of ≥71 on the 7-field/4-wide field color fundus photographs assessment by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% CI is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| ITT Population | 0.4 (0.0 to 1.2) | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
| Treatment-Naive Population | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
| Percentage of participants | B: Faricimab 6 mg PTI |
|---|---|
| Once Every 4 Weeks | 10.8 (7.2 to 14.4) |
| Once Every 8 Weeks | 15.4 (11.2 to 19.6) |
| Once Every 12 Weeks | 21.0 (16.3 to 25.7) |
| Once Every 16 Weeks | 52.8 (47.0 to 58.6) |
| Percentage of participants | B: Faricimab 6 mg PTI |
|---|---|
| Once Every 4 Weeks | 9.0 (5.2 to 12.8) |
| Once Every 8 Weeks | 14.4 (9.8 to 19.0) |
| Once Every 12 Weeks | 22.1 (16.6 to 27.5) |
| Once Every 16 Weeks | 54.5 (47.9 to 61.1) |
| Percentage of participants | B: Faricimab 6 mg PTI |
|---|---|
| Once Every 4 Weeks | 7.0 (4.0 to 10.1) |
| Once Every 8 Weeks | 14.8 (10.6 to 19.1) |
| Once Every 12 Weeks | 18.1 (13.5 to 22.8) |
| Once Every 16 Weeks | 60.0 (54.1 to 65.9) |
| Percentage of participants | B: Faricimab 6 mg PTI |
|---|---|
| Once Every 4 Weeks | 7.2 (3.7 to 10.7) |
| Once Every 8 Weeks | 11.1 (6.8 to 15.3) |
| Once Every 12 Weeks | 16.8 (11.7 to 21.9) |
| Once Every 16 Weeks | 64.9 (58.4 to 71.4) |
| Percentage of participants | B: Faricimab 6 mg PTI |
|---|---|
| ITT Population | 67.8 (62.4 to 73.3) |
| Treatment-Naive Population | 71.6 (65.7 to 77.6) |
| Percentage of participants | B: Faricimab 6 mg PTI |
|---|---|
| ITT Population | 60.4 (54.5 to 66.2) |
| Treatment-Naive Population | 64.4 (57.9 to 70.9) |
Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment (U.S. and Canada vs. the rest of the world; Asia and rest of the world regions were combined). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.04% CI.
| microns | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| ITT Population | -206.6 (-214.7 to -198.4) | -196.5 (-204.7 to -188.4) | -170.3 (-178.5 to -162.2) |
| Treatment-Naive Population | -204.6 (-213.5 to -195.7) | -197.5 (-206.2 to -188.8) | -173.6 (-182.3 to -164.8) |
Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment (U.S. and Canada vs. the rest of the world; Asia and rest of the world regions were combined). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.04% CI.
| microns | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 4 | -118.4 (-128.5 to -108.2) | -124.9 (-135.0 to -114.8) | -111.0 (-121.2 to -100.8) |
| Week 8 | -145.9 (-155.2 to -136.5) | -149.6 (-159.0 to -140.3) | -130.9 (-140.4 to -121.5) |
| Week 12 | -165.6 (-174.3 to -156.9) | -168.4 (-177.1 to -159.8) | -144.7 (-153.4 to -136.0) |
| Week 16 | -177.6 (-186.0 to -169.2) | -182.1 (-190.4 to -173.7) | -152.7 (-161.1 to -144.3) |
| Week 20 | -184.6 (-193.2 to -176.1) | -174.6 (-183.1 to -166.0) | -159.0 (-167.6 to -150.4) |
| Week 24 | -196.4 (-204.8 to -188.0) | -192.8 (-201.2 to -184.3) | -146.3 (-154.7 to -137.8) |
| Week 28 | -174.6 (-184.4 to -164.9) | -193.7 (-203.4 to -184.0) | -163.8 (-173.6 to -154.0) |
| Week 32 | -200.2 (-209.4 to -191.0) | -181.6 (-190.8 to -172.4) | -147.2 (-156.4 to -138.0) |
| Week 36 | -179.4 (-188.9 to -169.8) | -201.0 (-210.6 to -191.5) | -166.0 (-175.7 to -156.4) |
| Week 40 | -205.1 (-214.5 to -195.7) | -193.5 (-203.0 to -184.1) | -153.9 (-163.4 to -144.4) |
| Week 44 | -187.5 (-197.4 to -177.5) | -189.2 (-199.1 to -179.3) | -172.6 (-182.6 to -162.6) |
| Week 48 | -209.7 (-218.6 to -200.8) | -194.8 (-203.7 to -185.8) | -163.2 (-172.2 to -154.3) |
| Week 52 | -191.0 (-200.6 to -181.4) | -193.0 (-202.6 to -183.4) | -179.2 (-188.9 to -169.5) |
| Week 56 | -212.4 (-221.5 to -203.4) | -200.3 (-209.3 to -191.2) | -164.4 (-173.5 to -155.2) |
| Week 60 | -197.8 (-207.4 to -188.2) | -196.3 (-205.9 to -186.6) | -182.0 (-191.7 to -172.3) |
| Week 64 | -214.9 (-224.0 to -205.9) | -199.9 (-208.9 to -190.8) | -171.5 (-180.6 to -162.4) |
| Week 68 | -201.1 (-210.0 to -192.3) | -200.9 (-209.7 to -192.1) | -186.8 (-195.7 to -177.9) |
| Week 72 | -216.2 (-224.9 to -207.6) | -201.6 (-210.3 to -193.0) | -182.3 (-191.1 to -173.6) |
| Week 76 | -206.0 (-215.1 to -197.0) | -200.7 (-209.8 to -191.7) | -188.4 (-197.6 to -179.3) |
| Week 80 | -219.1 (-227.7 to -210.5) | -203.2 (-211.7 to -194.6) | -184.5 (-193.2 to -175.9) |
| Week 84 | -211.8 (-221.1 to -202.5) | -204.9 (-214.1 to -195.7) | -186.2 (-195.5 to -176.9) |
| Week 88 | -218.6 (-228.0 to -209.3) | -204.1 (-213.4 to -194.8) | -183.7 (-193.1 to -174.3) |
| Week 92 | -210.9 (-220.1 to -201.7) | -202.4 (-211.4 to -193.3) | -193.9 (-203.2 to -184.7) |
| Week 96 | -224.0 (-232.9 to -215.1) | -203.8 (-212.6 to -195.1) | -194.7 (-203.6 to -185.8) |
| Week 100 | -213.1 (-221.8 to -204.3) | -207.3 (-216.0 to -198.6) | -200.2 (-209.0 to -191.4) |
Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (\<64 vs. ≥64 letters), and region of enrollment (U.S. and Canada vs. the rest of the world; Asia and rest of the world regions were combined). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.04% CI.
| microns | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 4 | -116.1 (-127.0 to -105.2) | -121.5 (-132.1 to -110.9) | -110.1 (-120.9 to -99.3) |
| Week 8 | -142.9 (-153.0 to -132.8) | -147.4 (-157.3 to -137.5) | -131.5 (-141.5 to -121.5) |
| Week 12 | -162.8 (-171.9 to -153.6) | -166.7 (-175.7 to -157.8) | -147.4 (-156.4 to -138.3) |
| Week 16 | -175.1 (-183.8 to -166.3) | -181.7 (-190.3 to -173.1) | -155.9 (-164.5 to -147.2) |
| Week 20 | -182.9 (-192.0 to -173.8) | -178.1 (-187.0 to -169.2) | -161.6 (-170.6 to -152.6) |
| Week 24 | -194.2 (-203.4 to -184.9) | -191.1 (-200.2 to -182.0) | -149.7 (-158.9 to -140.6) |
| Week 28 | -177.4 (-188.1 to -166.7) | -194.0 (-204.4 to -183.5) | -167.5 (-178.0 to -156.9) |
| Week 32 | -196.4 (-206.6 to -186.2) | -183.7 (-193.7 to -173.8) | -150.2 (-160.3 to -140.2) |
| Week 36 | -181.9 (-191.9 to -171.9) | -203.6 (-213.3 to -193.8) | -168.7 (-178.6 to -158.9) |
| Week 40 | -198.9 (-209.7 to -188.1) | -192.1 (-202.8 to -181.4) | -157.4 (-168.2 to -146.5) |
| Week 44 | -187.3 (-198.5 to -176.1) | -189.3 (-200.2 to -178.3) | -172.9 (-184.0 to -161.8) |
| Week 48 | -207.3 (-217.3 to -197.3) | -194.9 (-204.7 to -185.1) | -165.0 (-174.9 to -155.1) |
| Week 52 | -191.1 (-201.7 to -180.5) | -196.2 (-206.5 to -185.9) | -181.1 (-191.6 to -170.5) |
| Week 56 | -210.4 (-220.0 to -200.8) | -200.9 (-210.3 to -191.5) | -171.0 (-180.6 to -161.4) |
| Week 60 | -195.0 (-205.6 to -184.4) | -198.0 (-208.4 to -187.5) | -185.1 (-195.6 to -174.5) |
| Week 64 | -213.7 (-223.5 to -203.9) | -199.2 (-208.8 to -189.6) | -175.3 (-184.9 to -165.6) |
| Week 68 | -201.5 (-211.2 to -191.7) | -201.7 (-211.2 to -192.1) | -189.1 (-198.8 to -179.5) |
| Week 72 | -215.9 (-225.5 to -206.4) | -203.2 (-212.5 to -193.9) | -184.1 (-193.5 to -174.6) |
| Week 76 | -204.8 (-214.8 to -194.9) | -202.1 (-211.8 to -192.4) | -189.8 (-199.7 to -180.0) |
| Week 80 | -217.3 (-227.0 to -207.5) | -202.2 (-211.6 to -192.7) | -186.2 (-195.9 to -176.6) |
| Week 84 | -211.0 (-221.6 to -200.4) | -202.9 (-213.2 to -192.7) | -185.7 (-196.1 to -175.2) |
| Week 88 | -215.9 (-226.4 to -205.5) | -205.2 (-215.3 to -195.0) | -186.4 (-196.7 to -176.1) |
| Week 92 | -208.8 (-218.9 to -198.7) | -202.2 (-212.0 to -192.5) | -195.9 (-205.9 to -186.0) |
| Week 96 | -221.0 (-231.4 to -210.7) | -199.0 (-209.0 to -189.1) | -196.7 (-206.9 to -186.6) |
| Week 100 | -213.4 (-222.7 to -204.1) | -206.7 (-215.7 to -197.7) | -201.3 (-210.5 to -192.1) |
Absence of diabetic macular edema was defined as achieving a central subfield thickness (CST) of \<325 microns in the study eye. CST was defined as the distance between the internal limiting membrane and Bruch's membrane. For each participant, an average CST value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| ITT Population | 81.3 (76.8 to 85.9) | 78.0 (73.1 to 82.8) | 65.4 (59.9 to 70.8) |
| Treatment-Naive Population | 83.5 (78.4 to 88.5) | 80.4 (75.1 to 85.7) | 68.3 (62.1 to 74.4) |
Absence of diabetic macular edema was defined as achieving a central subfield thickness of \<325 microns in the study eye. Central subfield thickness was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 4 | 36.1 (30.8 to 41.4) | 41.3 (35.9 to 46.8) | 35.0 (29.7 to 40.4) |
| Week 8 | 48.4 (42.9 to 54.0) | 52.7 (47.2 to 58.2) | 42.6 (37.1 to 48.2) |
| Week 12 | 60.9 (55.4 to 66.4) | 67.4 (62.1 to 72.6) | 49.6 (44.0 to 55.2) |
| Week 16 | 67.2 (61.8 to 72.5) | 72.0 (66.9 to 77.0) | 58.6 (53.1 to 64.1) |
| Week 20 | 71.1 (65.9 to 76.2) | 70.7 (65.6 to 75.8) | 58.9 (53.4 to 64.5) |
| Week 24 | 76.5 (71.7 to 81.4) | 81.3 (76.8 to 85.8) | 53.7 (48.1 to 59.4) |
| Week 28 | 71.4 (66.2 to 76.5) | 79.3 (74.6 to 84.0) | 62.5 (57.0 to 68.0) |
| Week 32 | 79.0 (74.2 to 83.8) | 72.1 (66.8 to 77.4) | 55.8 (50.1 to 61.5) |
| Week 36 | 70.9 (65.6 to 76.1) | 81.7 (77.1 to 86.3) | 63.1 (57.4 to 68.8) |
| Week 40 | 82.3 (77.9 to 86.7) | 80.8 (76.1 to 85.5) | 58.8 (53.0 to 64.7) |
| Week 44 | 74.7 (69.6 to 79.9) | 79.0 (74.3 to 83.8) | 67.6 (62.1 to 73.1) |
| Week 48 | 86.5 (82.5 to 90.5) | 81.5 (76.8 to 86.1) | 64.0 (58.3 to 69.7) |
| Week 52 | 77.4 (72.4 to 82.4) | 78.3 (73.4 to 83.1) | 71.1 (65.6 to 76.7) |
| Week 56 | 86.5 (82.4 to 90.7) | 81.3 (76.6 to 86.0) | 65.0 (59.2 to 70.8) |
| Week 60 | 78.8 (74.0 to 83.6) | 79.4 (74.6 to 84.3) | 72.3 (66.9 to 77.7) |
| Week 64 | 88.3 (84.4 to 92.2) | 80.0 (75.2 to 84.8) | 67.7 (62.1 to 73.3) |
| Week 68 | 83.5 (79.0 to 88.1) | 84.1 (79.7 to 88.5) | 74.8 (69.4 to 80.1) |
| Week 72 | 88.0 (84.0 to 92.0) | 85.2 (81.0 to 89.5) | 70.2 (64.5 to 75.9) |
| Week 76 | 85.6 (81.3 to 89.8) | 84.9 (80.5 to 89.2) | 76.0 (70.7 to 81.2) |
| Week 80 | 88.5 (84.5 to 92.4) | 81.9 (77.3 to 86.6) | 73.2 (67.7 to 78.7) |
| Week 84 | 85.1 (80.7 to 89.5) | 86.1 (82.0 to 90.3) | 74.9 (69.5 to 80.3) |
| Week 88 | 90.4 (86.8 to 94.0) | 83.2 (78.7 to 87.7) | 74.2 (68.7 to 79.6) |
| Week 92 | 86.5 (82.3 to 90.7) | 78.2 (73.2 to 83.3) | 78.2 (73.1 to 83.3) |
| Week 96 | 91.8 (88.4 to 95.3) | 83.7 (79.2 to 88.2) | 77.3 (72.1 to 82.4) |
| Week 100 | 89.5 (85.7 to 93.4) | 85.9 (81.7 to 90.1) | 81.0 (76.1 to 86.0) |
Retinal dryness was defined as achieving a central subfield thickness (ILM-BM) of \<280 microns. Central subfield thickness was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. The weighted estimates of the percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 4 | 15.4 (11.5 to 19.4) | 16.0 (12.0 to 19.9) | 12.6 (8.9 to 16.3) |
| Week 8 | 24.2 (19.6 to 28.8) | 24.6 (19.9 to 29.3) | 16.2 (12.1 to 20.3) |
| Week 12 | 32.4 (27.3 to 37.5) | 34.1 (28.9 to 39.4) | 22.1 (17.4 to 26.7) |
| Week 16 | 38.4 (33.0 to 43.9) | 42.5 (36.9 to 48.0) | 23.2 (18.5 to 27.9) |
| Week 20 | 45.9 (40.3 to 51.5) | 40.6 (35.0 to 46.1) | 29.7 (24.5 to 34.8) |
| Week 24 | 53.0 (47.3 to 58.7) | 48.1 (42.4 to 53.8) | 26.6 (21.6 to 31.6) |
| Week 28 | 45.9 (40.1 to 51.7) | 50.2 (44.4 to 55.9) | 34.3 (28.8 to 39.8) |
| Week 32 | 55.0 (49.1 to 60.8) | 43.2 (37.3 to 49.0) | 30.6 (25.1 to 36.1) |
| Week 36 | 48.5 (42.5 to 54.5) | 54.3 (48.4 to 60.3) | 39.2 (33.4 to 45.1) |
| Week 40 | 57.5 (51.8 to 63.2) | 51.3 (45.3 to 57.3) | 32.2 (26.7 to 37.7) |
| Week 44 | 51.5 (45.7 to 57.4) | 51.9 (46.1 to 57.8) | 37.1 (31.4 to 42.8) |
| Week 48 | 63.2 (57.4 to 69.0) | 50.1 (44.2 to 56.0) | 36.2 (30.4 to 42.0) |
| Week 52 | 57.8 (51.9 to 63.7) | 54.7 (48.7 to 60.6) | 42.3 (36.2 to 48.4) |
| Week 56 | 66.3 (60.6 to 72.0) | 56.9 (51.0 to 62.9) | 41.2 (35.1 to 47.2) |
| Week 60 | 60.2 (54.4 to 66.0) | 54.0 (48.0 to 60.0) | 47.7 (41.6 to 53.7) |
| Week 64 | 68.5 (62.8 to 74.1) | 55.4 (49.4 to 61.3) | 47.4 (41.3 to 53.4) |
| Week 68 | 61.3 (55.3 to 67.3) | 57.7 (51.7 to 63.8) | 52.3 (46.1 to 58.5) |
| Week 72 | 65.8 (60.1 to 71.5) | 58.5 (52.6 to 64.3) | 47.7 (41.4 to 53.9) |
| Week 76 | 65.9 (60.1 to 71.8) | 54.8 (48.6 to 60.9) | 53.9 (47.7 to 60.1) |
| Week 80 | 70.1 (64.5 to 75.8) | 54.7 (48.7 to 60.6) | 51.1 (44.8 to 57.3) |
| Week 84 | 67.1 (61.3 to 72.9) | 61.2 (55.5 to 67.0) | 56.0 (49.9 to 62.2) |
| Week 88 | 72.2 (66.7 to 77.7) | 58.0 (52.1 to 64.0) | 54.2 (48.0 to 60.5) |
| Week 92 | 66.2 (60.5 to 72.0) | 58.0 (52.2 to 63.8) | 57.9 (51.7 to 64.0) |
| Week 96 | 72.7 (67.2 to 78.2) | 61.4 (55.6 to 67.2) | 58.0 (51.8 to 64.2) |
| Week 100 | 71.4 (65.9 to 76.8) | 60.5 (54.5 to 66.4) | 60.7 (54.5 to 66.8) |
Intraretinal fluid was measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world); Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 16 | 16.3 (12.0 to 20.5) | 21.9 (17.1 to 26.6) | 13.4 (9.6 to 17.3) |
| Week 48 | 45.6 (39.7 to 51.6) | 33.2 (27.5 to 38.9) | 21.9 (17.0 to 26.9) |
| Week 52 | 42.1 (36.3 to 47.9) | 38.8 (32.9 to 44.7) | 25.5 (20.2 to 30.8) |
| Week 56 | 49.3 (43.3 to 55.3) | 42.7 (36.7 to 48.7) | 23.7 (18.5 to 28.9) |
| Week 92 | 58.5 (52.3 to 64.7) | 43.2 (37.1 to 49.3) | 33.2 (27.4 to 39.1) |
| Week 96 | 63.1 (57.0 to 69.2) | 47.6 (41.5 to 53.7) | 34.6 (28.7 to 40.6) |
| Week 100 | 61.4 (55.2 to 67.5) | 44.5 (38.4 to 50.7) | 37.6 (31.5 to 43.6) |
Subretinal fluid was measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world); Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 16 | 95.3 (92.9 to 97.7) | 94.5 (92.0 to 97.1) | 95.9 (93.7 to 98.2) |
| Week 48 | 97.0 (95.0 to 99.0) | 95.5 (93.1 to 97.9) | 96.2 (93.8 to 98.5) |
| Week 52 | 95.8 (93.3 to 98.2) | 95.4 (92.9 to 97.9) | 98.0 (96.2 to 99.7) |
| Week 56 | 97.0 (95.0 to 99.0) | 97.0 (95.0 to 99.0) | 97.3 (95.3 to 99.3) |
| Week 92 | 94.8 (92.1 to 97.6) | 94.5 (91.7 to 97.3) | 96.7 (94.5 to 99.0) |
| Week 96 | 97.0 (94.8 to 99.1) | 94.1 (91.3 to 97.0) | 96.7 (94.5 to 98.9) |
| Week 100 | 94.3 (91.4 to 97.2) | 97.3 (95.4 to 99.2) | 97.1 (95.0 to 99.2) |
Intraretinal fluid and subretinal fluid were measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world); Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 16 | 15.9 (11.7 to 20.1) | 21.9 (17.1 to 26.6) | 13.1 (9.3 to 16.9) |
| Week 48 | 45.2 (39.3 to 51.2) | 32.4 (26.8 to 38.1) | 21.9 (17.0 to 26.9) |
| Week 52 | 42.1 (36.3 to 47.9) | 38.0 (32.2 to 43.8) | 25.5 (20.2 to 30.8) |
| Week 56 | 47.0 (41.0 to 53.0) | 42.4 (36.4 to 48.3) | 23.7 (18.5 to 28.9) |
| Week 92 | 57.2 (51.0 to 63.4) | 41.3 (35.2 to 47.3) | 32.0 (26.3 to 37.8) |
| Week 96 | 62.4 (56.2 to 68.5) | 46.0 (39.8 to 52.1) | 34.2 (28.3 to 40.1) |
| Week 100 | 59.3 (53.0 to 65.5) | 43.8 (37.6 to 49.9) | 37.4 (31.4 to 43.5) |
The NEI VFQ-25 captures a patient's perception of vision-related functioning and quality of life. The core measure includes 25 items that comprise 11 vision-related subscales and one item on general health. The composite score ranges from 0 to 100, with higher scores, or a positive change from baseline, indicating better vision-related functioning. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline NEI VFQ-25 Composite Score (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% CI is a rounding of 95.04% CI.
| score on a scale | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Week 24 | 6.0 (4.8 to 7.2) | 6.9 (5.7 to 8.1) | 6.0 (4.8 to 7.2) |
| Week 52 | 7.3 (5.9 to 8.6) | 7.9 (6.6 to 9.3) | 7.5 (6.1 to 8.9) |
| Week 100 | 8.0 (6.6 to 9.4) | 7.4 (6.0 to 8.8) | 7.6 (6.1 to 9.0) |
This analysis of adverse events (AEs) includes both ocular and non-ocular (systemic) AEs. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. AEs of special interest included the following: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law; Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Adverse Event (AE) | 92.7 | 91.4 | 89.1 |
| Serious AE (SAE) | 35.5 | 37.4 | 29.9 |
| AE Leading to Withdrawal from Study Treatment | 2.6 | 2.9 | 1.6 |
| AE of Special Interest (AESI) | 6.1 | 7.0 | 4.8 |
This analysis of adverse events (AEs) only includes ocular AEs, which are categorized as having occurred either in the study eye or the fellow eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. Ocular AEs of special interest included the following: Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Study Eye: Adverse Event (AE) | 47.0 | 46.6 | 46.3 |
| Study Eye: Serious AE (SAE) | 3.8 | 4.5 | 2.3 |
| Study Eye: AE Leading to Withdrawal from Treatment | 1.3 | 1.9 | 0.3 |
| Study Eye: Treatment-related AE | 3.2 | 2.2 | 1.9 |
| Study Eye: Treatment-related SAE | 0.0 | 1.3 | 0.0 |
| Study Eye: AE of Special Interest (AESI) | 3.5 | 4.2 | 2.6 |
| Study Eye: AESI, Drop in VA Score ≥30 Letters | 2.6 | 2.2 | 2.3 |
| Study Eye: AESI, Associated with Severe IOI | 0.6 | 1.6 | 0.0 |
| Study Eye: AESI, Intervention Req. to Prevent Permanent Vision Loss | 1.0 | 1.3 | 0.3 |
| Fellow Eye: AE | 40.3 | 42.2 | 46.3 |
| Fellow Eye: SAE | 2.9 | 3.5 | 2.3 |
| Fellow Eye: AESI | 2.9 | 2.9 | 2.3 |
| Fellow Eye: AESI, Drop in VA Score ≥30 Letters | 2.2 | 1.9 | 1.3 |
| Fellow Eye: AESI, Associated with Severe IOI | 0.0 | 0.3 | 0.0 |
| Fellow Eye: AESI, Intervention Req. to Prevent Permanent Vision Loss | 1.0 | 1.3 | 1.0 |
This analysis of adverse events (AEs) only includes non-ocular (systemic) AEs. Investigators sought information on adverse events (AEs) at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. The non-ocular AE of special interest was: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| Adverse Event (AE) | 76.7 | 80.2 | 77.8 |
| Serious AE (SAE) | 31.6 | 31.0 | 27.0 |
| AE Leading to Withdrawal from Study Treatment | 1.3 | 1.0 | 1.3 |
| AE of Special Interest (AESI) | 0.0 | 0.0 | 0.3 |
| AESI, Elevated ALT or AST with Either Elevated Bilirubin or Clinical Jaundice | 0.0 | 0.0 | 0.3 |
Faricimab concentration in plasma was determined using a validated immunoassay method.
| micrograms per millilitre (μg/mL) | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI |
|---|---|---|
| Baseline | 0.0000 ± 0.0001 | 0.0000 ± 0.0001 |
| Week 4 | 0.0211 ± 0.0337 | 0.0181 ± 0.0139 |
| Week 28 | 0.0033 ± 0.0053 | 0.0089 ± 0.0145 |
| Week 52 | 0.0052 ± 0.0104 | 0.0100 ± 0.0132 |
| Week 76 | 0.0048 ± 0.0085 | 0.0068 ± 0.0255 |
| Week 100 | 0.0052 ± 0.0087 | 0.0077 ± 0.0126 |
Anti-drug antibodies (ADAs) against fariciamb were detected in plasma using a validated bridging enzyme-linked immunosorbent assay (ELISA). The percentage of participants with treatment-emergent ADA-positive samples includes post-baseline evaluable participants with at least one treatment-induced (defined as having an ADA-negative sample or missing sample at baseline and any positive post-baseline sample) or treatment-boosted (defined as having an ADA-positive sample at baseline and any positive post-baseline sample with a titer that is equal to or greater than 4-fold baseline titer) ADA-positive sample during the study treatment period.
| Percentage of participants | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI |
|---|---|---|
| Total Treatment-Emergent ADA-Positive | 12.6 | 10.6 |
| Treatment-Induced ADA-Positive | 12.6 | 10.3 |
| Treatment-Boosted ADA-Positive | 0.0 | 0.3 |
Collected over From Baseline until Week 100. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| A: Faricimab 6 mg Q8W | 16/313 (5.1%) | 111/313 (35.5%) | 161/313 (51.4%) |
| B: Faricimab 6 mg PTI | 21/313 (6.7%) | 117/313 (37.4%) | 163/313 (52.1%) |
| C: Aflibercept 2 mg Q8W | 13/311 (4.2%) | 93/311 (29.9%) | 163/311 (52.4%) |
| Event | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| COVID-19Infections and infestations | 5/313 | 10/313 | 4/311 |
| PneumoniaInfections and infestations | 8/313 | 4/313 | 7/311 |
| OsteomyelitisInfections and infestations | 3/313 | 1/313 | 7/311 |
| SepsisInfections and infestations | 6/313 | 0/313 | 7/311 |
| Cardiac failure congestiveCardiac disorders | 7/313 | 3/313 | 5/311 |
| Myocardial infarctionCardiac disorders | 2/313 | 5/313 | 5/311 |
| Acute myocardial infarctionCardiac disorders | 5/313 | 3/313 | 4/311 |
| Coronary artery diseaseCardiac disorders | 2/313 | 5/313 | 4/311 |
| DeathGeneral disorders | 3/313 | 5/313 | 1/311 |
| CellulitisInfections and infestations | 4/313 | 5/313 | 4/311 |
| Event | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W |
|---|---|---|---|
| CataractEye disorders | 58/313 | 47/313 | 55/311 |
| HypertensionVascular disorders | 22/313 | 32/313 | 36/311 |
| Diabetic retinal oedemaEye disorders | 20/313 | 29/313 | 33/311 |
| Conjunctival haemorrhageEye disorders | 25/313 | 33/313 | 24/311 |
| NasopharyngitisInfections and infestations | 27/313 | 18/313 | 30/311 |
| Vitreous detachmentEye disorders | 20/313 | 23/313 | 13/311 |
| Urinary tract infectionInfections and infestations | 14/313 | 15/313 | 19/311 |
| FallInjury, poisoning and procedural complications | 16/313 | 19/313 | 9/311 |
| Vitreous floatersEye disorders | 17/313 | 11/313 | 10/311 |
| Intraocular pressure increasedInvestigations | 17/313 | 13/313 | 11/311 |
The overall number of baseline participants (940) comprises the Intent-to-Treat (ITT) Population, which includes all global participants who were randomized in the study, grouped according to the treatment assigned at randomization.
| Age, Continuous(Years) | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W | Total |
|---|---|---|---|---|
| ITT Population | 61.6 ± 9.5 | 62.8 ± 10.0 | 62.2 ± 9.6 | 62.2 ± 9.7 |
| Treatment-Naive Population | 61.0 ± 9.6 | 62.5 ± 10.3 | 62.2 ± 9.9 | 61.9 ± 10.0 |
| Sex: Female, Male(Participants) | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W | Total |
|---|---|---|---|---|
| ITT Population — Female | 128 | 116 | 134 | 378 |
| ITT Population — Male | 187 | 197 | 178 | 562 |
| Treatment-Naive Population — Female | 93 | 91 | 108 | 292 |
| Treatment-Naive Population — Male | 145 | 154 | 134 | 433 |
| Ethnicity (NIH/OMB)(Participants) | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W | Total |
|---|---|---|---|---|
| ITT Population — Hispanic or Latino | 37 | 40 | 37 | 114 |
| ITT Population — Not Hispanic or Latino | 273 | 268 | 272 | 813 |
| ITT Population — Unknown or Not Reported | 5 | 5 | 3 | 13 |
| Treatment-Naive Population — Hispanic or Latino | 31 | 32 | 31 | 94 |
| Treatment-Naive Population — Not Hispanic or Latino | 202 | 210 | 208 | 620 |
| Treatment-Naive Population — Unknown or Not Reported | 5 | 3 | 3 | 11 |
| Race (NIH/OMB)(Participants) | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W | Total |
|---|---|---|---|---|
| ITT Population — American Indian or Alaska Native | 6 | 5 | 7 | 18 |
| ITT Population — Asian | 31 | 26 | 27 | 84 |
| ITT Population — Native Hawaiian or Other Pacific Islander | 2 | 0 | 3 | 5 |
| ITT Population — Black or African American | 22 | 25 | 12 | 59 |
| ITT Population — White | 241 | 240 | 253 | 734 |
| ITT Population — More than one race | 0 | 1 | 0 | 1 |
| ITT Population — Unknown or Not Reported | 13 | 16 | 10 | 39 |
| Treatment-Naive Population — American Indian or Alaska Native | 4 | 3 | 6 | 13 |
| Treatment-Naive Population — Asian | 21 | 18 | 20 | 59 |
| Treatment-Naive Population — Native Hawaiian or Other Pacific Islander | 2 | 0 | 2 | 4 |
| Treatment-Naive Population — Black or African American | 17 | 24 | 9 | 50 |
| Treatment-Naive Population — White | 181 | 186 | 196 | 563 |
| Treatment-Naive Population — More than one race | 0 | 1 | 0 | 1 |
| Treatment-Naive Population — Unknown or Not Reported | 13 | 13 | 9 | 35 |
| Number of Participants by Previous Treatment Status with Intravitreal Anti-VEGF Agents(Participants) | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W | Total |
|---|---|---|---|---|
| Treatment-Naive | 238 | 245 | 242 | 725 |
| Previously Treated | 77 | 68 | 70 | 215 |
| Region of Enrollment(Participants) | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W | Total |
|---|---|---|---|---|
| ITT Population — United States and Canada | 167 | 168 | 168 | 503 |
| ITT Population — Asia | 21 | 19 | 20 | 60 |
| ITT Population — Rest of the World | 127 | 126 | 124 | 377 |
| Treatment-Naive Population — United States and Canada | 130 | 134 | 135 | 399 |
| Treatment-Naive Population — Asia | 14 | 14 | 15 | 43 |
| Treatment-Naive Population — Rest of the World | 94 | 97 | 92 | 283 |
| Number of Participants by the Eye Chosen as the Study Eye (Left or Right)(Participants) | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W | Total |
|---|---|---|---|---|
| ITT Population — Left Eye | 150 | 172 | 151 | 473 |
| ITT Population — Right Eye | 165 | 141 | 161 | 467 |
| Treatment-Naive Population — Left Eye | 117 | 130 | 117 | 364 |
| Treatment-Naive Population — Right Eye | 121 | 115 | 125 | 361 |
| Baseline Best Corrected Visual Acuity (BCVA) Letter Score in the Study Eye(ETDRS Letters) | A: Faricimab 6 mg Q8W | B: Faricimab 6 mg PTI | C: Aflibercept 2 mg Q8W | Total |
|---|---|---|---|---|
| ITT Population | 62.0 ± 9.9 | 61.9 ± 10.2 | 62.2 ± 9.5 | 62.0 ± 9.9 |
| Treatment-Naive Population | 62.3 ± 9.9 | 61.8 ± 10.7 | 62.6 ± 9.2 | 62.2 ± 9.9 |
3 further baseline measures are reported on the registry.
Showing the first 100 of 185 sites across 16 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Sep 2018 to primary completion in Oct 2020, 25 months.
Results were first posted in Mar 2022, 1 year 5 months after primary completion. A results delay was requested in Sep 2021.
Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's 25 months is close to that.
Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Faricimab